<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Mediators Inflamm</journal-id><journal-id journal-id-type="iso-abbrev">Mediators Inflamm</journal-id><journal-id journal-id-type="publisher-id">MI</journal-id><journal-title-group><journal-title>Mediators of Inflammation</journal-title></journal-title-group><issn pub-type="ppub">0962-9351</issn><issn pub-type="epub">1466-1861</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26903712</article-id><article-id pub-id-type="pmc">4745915</article-id><article-id pub-id-type="doi">10.1155/2016/6789276</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>12 Weeks of Combined Endurance and Resistance Training Reduces Innate Markers of Inflammation in a Randomized Controlled Clinical Trial in Patients with Multiple Sclerosis</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9789-3479</contrib-id><name><surname>Deckx</surname><given-names>Nathalie</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wens</surname><given-names>Inez</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Nuyts</surname><given-names>Amber H.</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hens</surname><given-names>Niel</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>De Winter</surname><given-names>Benedicte Y.</given-names></name><xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Koppen</surname><given-names>Gudrun</given-names></name><xref ref-type="aff" rid="I6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Goossens</surname><given-names>Herman</given-names></name><xref ref-type="aff" rid="I7">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Van Damme</surname><given-names>Pierre</given-names></name><xref ref-type="aff" rid="I8">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Berneman</surname><given-names>Zwi N.</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Eijnde</surname><given-names>Bert O.</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0459-901X</contrib-id><name><surname>Cools</surname><given-names>Nathalie</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Laboratory of Experimental Hematology, Vaccine &amp; Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Wilrijk, Belgium</aff><aff id="I2"><sup>2</sup>REVAL Rehabilitation Research Centre, BIOMED Biomedical Research Institute, Faculty of Medicine and Life Sciences, Hasselt University, 3590 Diepenbeek, Belgium</aff><aff id="I3"><sup>3</sup>Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BIOSTAT), Hasselt University, 3590 Diepenbeek, Belgium</aff><aff id="I4"><sup>4</sup>Centre for Health Economic Research and Modelling Infectious Diseases (CHERMID), Vaccine &amp; Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Wilrijk, Belgium</aff><aff id="I5"><sup>5</sup>Laboratory of Experimental Medicine and Pediatrics, Division of Gastroenterology, Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Wilrijk, Belgium</aff><aff id="I6"><sup>6</sup>Flemish Institute for Technological Research (VITO), Environmental Risk and Health Unit, 2400 Mol, Belgium</aff><aff id="I7"><sup>7</sup>Laboratory of Medical Microbiology, Vaccine &amp; Infectious Diseases Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Wilrijk, Belgium</aff><aff id="I8"><sup>8</sup>Centre for the Evaluation of Vaccination, Vaccine &amp; Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Wilrijk, Belgium</aff><author-notes><corresp id="cor1">*Nathalie Cools: <email>nathalie.cools@uza.be</email></corresp><fn fn-type="other"><p>Academic Editor: Teresa Zelante</p></fn></author-notes><pub-date pub-type="ppub"><year>2016</year></pub-date><pub-date pub-type="epub"><day>20</day><month>1</month><year>2016</year></pub-date><volume>2016</volume><elocation-id>6789276</elocation-id><history><date date-type="received"><day>31</day><month>8</month><year>2015</year></date><date date-type="rev-recd"><day>30</day><month>11</month><year>2015</year></date><date date-type="accepted"><day>7</day><month>12</month><year>2015</year></date></history><permissions><copyright-statement>Copyright © 2016 Nathalie Deckx et al.</copyright-statement><copyright-year>2016</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><offsets xml_i="5998" xml_f="6696" txt_i="11" txt_f="709">Previously, we reported that patients with multiple sclerosis (MS) demonstrate improved muscle strength, exercise tolerance, and lean tissue mass following a combined endurance and resistance exercise program. However, the effect of exercise on the underlying disease pathogenesis remains elusive. Since recent evidence supports a crucial role of dendritic cells (DC) in the pathogenesis of MS, we investigated the effect of a 12-week combined exercise program in MS patients on the number and function of DC. We demonstrate an increased number of plasmacytoid DC (pDC) following the exercise program. These pDC display an activated phenotype, as evidenced by increased numbers of circulating CD62L</offsets><sup><offsets xml_i="6701" xml_f="6702" txt_i="709" txt_f="710">+</offsets></sup><offsets xml_i="6708" xml_f="6717" txt_i="710" txt_f="719"> and CD80</offsets><sup><offsets xml_i="6722" xml_f="6723" txt_i="719" txt_f="720">+</offsets></sup><offsets xml_i="6729" xml_f="6768" txt_i="720" txt_f="759"> pDC. Interestingly, the number of CD80</offsets><sup><offsets xml_i="6773" xml_f="6774" txt_i="759" txt_f="760">+</offsets></sup><offsets xml_i="6780" xml_f="7022" txt_i="760" txt_f="1002"> pDC positively correlates with the presence of IL-10-producing regulatory type 1 cells (Tr1), an important cell type for maintaining peripheral tolerance to self-antigens. In addition, decreased production of the inflammatory mediators, TNF-</offsets><italic><offsets xml_i="7030" xml_f="7031" txt_i="1002" txt_f="1003">α</offsets></italic><offsets xml_i="7040" xml_f="7425" txt_i="1003" txt_f="1388"> and MMP-9, upon Toll-like receptor (TLR) stimulation was found at the end of the exercise program. Overall, our findings suggest that the 12-week exercise program reduces the secretion of inflammatory mediators upon TLR stimulation and promotes the immunoregulatory function of circulating pDC, suggestive for a favorable impact of exercise on the underlying immunopathogenesis of MS.</offsets></p></abstract></article-meta></front><body><sec id="sec1"><title><offsets xml_i="7491" xml_f="7506" txt_i="1396" txt_f="1411">1. Introduction</offsets></title><p><offsets xml_i="7517" xml_f="7930" txt_i="1412" txt_f="1825">Multiple sclerosis (MS) is a chronic demyelinating, inflammatory disease of the central nervous system (CNS), predominantly affecting young adults in their most productive years. It is a heterogeneous disease with regard to both its clinical course and symptoms. The most prevalent symptoms are sensory changes, including fatigue, balance disorders, spasticity, motor weakness, and impaired muscular performance [</offsets><xref rid="B1" ref-type="bibr"><offsets xml_i="7961" xml_f="7962" txt_i="1825" txt_f="1826">1</offsets></xref><offsets xml_i="7969" xml_f="8154" txt_i="1826" txt_f="2011">]. Besides incremental disability, these symptoms also result in a reduced quality of life. Nevertheless, a considerable part of MS symptoms may also result from a sedentary lifestyle [</offsets><xref rid="B2" ref-type="bibr"><offsets xml_i="8185" xml_f="8186" txt_i="2011" txt_f="2012">2</offsets></xref><offsets xml_i="8193" xml_f="8276" txt_i="2012" txt_f="2095">]. Over the years, different studies have reported improvement in muscle strength [</offsets><xref rid="B3" ref-type="bibr"><offsets xml_i="8307" xml_f="8308" txt_i="2095" txt_f="2096">3</offsets></xref><offsets xml_i="8315" xml_f="8341" txt_i="2096" txt_f="2122">], cardiovascular health [</offsets><xref rid="B4" ref-type="bibr"><offsets xml_i="8372" xml_f="8373" txt_i="2122" txt_f="2123">4</offsets></xref><offsets xml_i="8380" xml_f="8403" txt_i="2123" txt_f="2146">], mental functioning [</offsets><xref rid="B2" ref-type="bibr"><offsets xml_i="8434" xml_f="8435" txt_i="2146" txt_f="2147">2</offsets></xref><offsets xml_i="8442" xml_f="8466" txt_i="2147" txt_f="2171">], and quality of life [</offsets><xref rid="B5" ref-type="bibr"><offsets xml_i="8497" xml_f="8498" txt_i="2171" txt_f="2172">5</offsets></xref><offsets xml_i="8505" xml_f="8744" txt_i="2172" txt_f="2411">] following a physical exercise intervention in MS patients. Recently, we demonstrated improvement in muscle strength, exercise tolerance, and lean tissue mass in MS patients following a combined endurance and resistance exercise program [</offsets><xref rid="B6" ref-type="bibr"><offsets xml_i="8775" xml_f="8776" txt_i="2411" txt_f="2412">6</offsets></xref><offsets xml_i="8783" xml_f="8893" txt_i="2412" txt_f="2522">]. Although it is likely that only the effects of a sedentary lifestyle can be reversed by physical exercise [</offsets><xref rid="B7" ref-type="bibr"><offsets xml_i="8924" xml_f="8925" txt_i="2522" txt_f="2523">7</offsets></xref><offsets xml_i="8932" xml_f="9066" txt_i="2523" txt_f="2657">], it has been suggested that physical exercise might have the potential to have an impact on the disease pathogenesis of MS as well [</offsets><xref rid="B8" ref-type="bibr"><offsets xml_i="9097" xml_f="9098" txt_i="2657" txt_f="2658">8</offsets></xref><offsets xml_i="9105" xml_f="9228" txt_i="2658" txt_f="2781">]. To date, however, little is known about the potential effects of physical exercise on the underlying disease mechanisms.</offsets></p><p><offsets xml_i="9235" xml_f="9445" txt_i="2782" txt_f="2992">Although the exact cause of MS is still unknown, it is now generally accepted that MS is a complex multifactorial disease involving genetic and environmental factors affecting the autoreactive immune response [</offsets><xref rid="B9" ref-type="bibr"><offsets xml_i="9476" xml_f="9477" txt_i="2992" txt_f="2993">9</offsets></xref><offsets xml_i="9484" xml_f="9726" txt_i="2993" txt_f="3235">]. Based on previous efforts focusing on the role of the adaptive immune system in the pathogenesis of MS, it is currently well established that autoreactive T helper type 1 (Th1) and Th17 cells mediate the inflammatory processes in the CNS [</offsets><xref rid="B10" ref-type="bibr"><offsets xml_i="9758" xml_f="9760" txt_i="3235" txt_f="3237">10</offsets></xref><offsets xml_i="9767" xml_f="9928" txt_i="3237" txt_f="3398">]. Recent evidence also suggests involvement of innate immunity, including dendritic cells (DC), in the initiation and maintenance as well as progression of MS [</offsets><xref rid="B11" ref-type="bibr"><offsets xml_i="9960" xml_f="9962" txt_i="3398" txt_f="3400">11</offsets></xref><offsets xml_i="9969" xml_f="9971" txt_i="3400" txt_f="3402">].</offsets></p><p><offsets xml_i="9978" xml_f="10159" txt_i="3403" txt_f="3584">DC are professional antigen-presenting cells with the unique capacity to polarize the differentiation of T cells, thereby regulating the balance between inflammation and tolerance [</offsets><xref rid="B12" ref-type="bibr"><offsets xml_i="10191" xml_f="10193" txt_i="3584" txt_f="3586">12</offsets></xref><offsets xml_i="10200" xml_f="10694" txt_i="3586" txt_f="4080">]. To perform this function, DC are capable of capturing antigens, processing them, and presenting them on the cell surface complexed to major histocompatibility (MHC) molecules, for example, human leukocyte antigen- (HLA-) DR. Along with that, context-dependent expression of costimulatory molecules, such as CD80 and CD86, and secretion of cytokines occurs. In human blood, two major subsets of DC have been characterized, that is, myeloid or conventional DC (cDC) and plasmacytoid DC (pDC) [</offsets><xref rid="B13" ref-type="bibr"><offsets xml_i="10726" xml_f="10728" txt_i="4080" txt_f="4082">13</offsets></xref><offsets xml_i="10735" xml_f="11270" txt_i="4082" txt_f="4617">]. Both DC subsets display a different expression profile of cytokine receptors and cytokines, of migratory markers and migration potential, and of Toll-like receptors (TLR). In brief, cDC strongly express TLR2 and TLR4, among other TLR, which are stimulated by bacterial triacylated lipopeptides, Gram-negative bacterial lipopolysaccharide (LPS), fungal mannans, parasitic phospholipids, viral envelope proteins, and host-derived heat shock proteins. Upon activation, cDC secrete proinflammatory cytokines such as interleukin- (IL-) 1</offsets><italic><offsets xml_i="11278" xml_f="11279" txt_i="4617" txt_f="4618">β</offsets></italic><offsets xml_i="11288" xml_f="11341" txt_i="4618" txt_f="4671">, IL-6, IL-12p70, and tumour necrosis factor- (TNF-) </offsets><italic><offsets xml_i="11349" xml_f="11350" txt_i="4671" txt_f="4672">α</offsets></italic><offsets xml_i="11359" xml_f="11361" txt_i="4672" txt_f="4674"> [</offsets><xref rid="B13" ref-type="bibr"><offsets xml_i="11393" xml_f="11395" txt_i="4674" txt_f="4676">13</offsets></xref><offsets xml_i="11402" xml_f="11605" txt_i="4676" txt_f="4879">]. In addition, cDC also secrete the matrix metalloproteinase- (MMP-) 9, a protease that is involved in the breakdown of extracellular matrix in normal physiological processes, including cell migration [</offsets><xref rid="B14" ref-type="bibr"><offsets xml_i="11637" xml_f="11639" txt_i="4879" txt_f="4881">14</offsets></xref><offsets xml_i="11646" xml_f="11860" txt_i="4881" txt_f="5095">]. On the other hand, pDC express TLR7 and TLR9, which are stimulated by single-stranded RNA and unmethylated CpG oligodeoxynucleotides. Upon activation, pDC secrete significant amounts of type I interferon (IFN) [</offsets><xref rid="B15" ref-type="bibr"><offsets xml_i="11892" xml_f="11894" txt_i="5095" txt_f="5097">15</offsets></xref><offsets xml_i="11901" xml_f="12072" txt_i="5097" txt_f="5268">]. Depending on their costimulatory molecule expression and cytokine secretion, both cDC and pDC are able to induce effector T cells as well as regulatory T cells (Treg) [</offsets><xref rid="B12" ref-type="bibr"><offsets xml_i="12104" xml_f="12106" txt_i="5268" txt_f="5270">12</offsets></xref><offsets xml_i="12113" xml_f="12641" txt_i="5270" txt_f="5798">]. While in a steady state, both cDC and pDC are poor T cell stimulators, given their low expression levels of MHC and costimulatory molecules, activated cDC and pDC differ strongly in their T cell-stimulatory capacity. Following TLR ligation, activated cDC efficiently stimulate effector T cells as they upregulate the expression of costimulatory molecules and cytokines. On the other hand, TLR-mediated recognition of viral products and RNA/DNA/immunocomplexes by pDC results in the production of large amounts of type I IFN [</offsets><xref rid="B15" ref-type="bibr"><offsets xml_i="12673" xml_f="12675" txt_i="5798" txt_f="5800">15</offsets></xref><offsets xml_i="12682" xml_f="13017" txt_i="5800" txt_f="6135">]. For this, pDC effectively participate in antiviral immunity. Nevertheless, besides this protective role, pDC may also play a role in aberrant immune responses. For instance, it has been suggested that pDC promote the progression of systemic lupus erythematosus following sensing of self-DNA and subsequent production of type I IFN [</offsets><xref rid="B16" ref-type="bibr"><offsets xml_i="13049" xml_f="13051" txt_i="6135" txt_f="6137">16</offsets></xref><offsets xml_i="13058" xml_f="13220" txt_i="6137" txt_f="6299">]. In contrast, pDC have been implicated in maintenance of tolerance. It has been reported that pDC contribute to peripheral T cell tolerance in transplantation [</offsets><xref rid="B17" ref-type="bibr"><offsets xml_i="13252" xml_f="13254" txt_i="6299" txt_f="6301">17</offsets></xref><offsets xml_i="13261" xml_f="13279" txt_i="6301" txt_f="6319">], tumour escape [</offsets><xref rid="B18" ref-type="bibr"><offsets xml_i="13311" xml_f="13313" txt_i="6319" txt_f="6321">18</offsets></xref><offsets xml_i="13320" xml_f="13339" txt_i="6321" txt_f="6340">], oral tolerance [</offsets><xref rid="B19" ref-type="bibr"><offsets xml_i="13371" xml_f="13373" txt_i="6340" txt_f="6342">19</offsets></xref><offsets xml_i="13380" xml_f="13406" txt_i="6342" txt_f="6368">], and mucosal tolerance [</offsets><xref rid="B20" ref-type="bibr"><offsets xml_i="13438" xml_f="13440" txt_i="6368" txt_f="6370">20</offsets></xref><offsets xml_i="13447" xml_f="13584" txt_i="6370" txt_f="6507">]. Indeed, pDC display tolerogenic functions with the ability to indirectly suppress T cell proliferation through the induction of Treg [</offsets><xref rid="B21" ref-type="bibr"><offsets xml_i="13616" xml_f="13618" txt_i="6507" txt_f="6509">21</offsets></xref><offsets xml_i="13625" xml_f="13627" txt_i="6509" txt_f="6511">].</offsets></p><p><offsets xml_i="13634" xml_f="13694" txt_i="6512" txt_f="6572">Because of their unique capacity to shape immune responses [</offsets><xref rid="B12" ref-type="bibr"><offsets xml_i="13726" xml_f="13728" txt_i="6572" txt_f="6574">12</offsets></xref><offsets xml_i="13735" xml_f="14184" txt_i="6574" txt_f="7023">], DC are thought to play a pivotal role in the immunopathogenesis of several autoimmune disorders, including MS. Previously, we reported an aberrant frequency and expression of costimulatory markers on DC in the peripheral blood of MS patients. Circulating DC also display divergent expression of migration markers in MS patients as compared to DC from healthy controls. In addition, we demonstrated increased secretion of IL-12p70 by LPS- and IFN-</offsets><italic><offsets xml_i="14192" xml_f="14193" txt_i="7023" txt_f="7024">γ</offsets></italic><offsets xml_i="14202" xml_f="14292" txt_i="7024" txt_f="7114">-stimulated DC from relapsing-remitting (RR) MS patients as compared to healthy controls [</offsets><xref rid="B22" ref-type="bibr"><offsets xml_i="14324" xml_f="14326" txt_i="7114" txt_f="7116">22</offsets></xref><offsets xml_i="14333" xml_f="14389" txt_i="7116" txt_f="7172">]. Furthermore, upon stimulation with TLR9 ligands, IFN-</offsets><italic><offsets xml_i="14397" xml_f="14398" txt_i="7172" txt_f="7173">α</offsets></italic><offsets xml_i="14407" xml_f="14519" txt_i="7173" txt_f="7285"> secretion by pDC from RRMS patients is reduced as compared to the level secreted by pDC from healthy controls [</offsets><xref rid="B23" ref-type="bibr"><offsets xml_i="14551" xml_f="14553" txt_i="7285" txt_f="7287">23</offsets></xref><offsets xml_i="14560" xml_f="14562" txt_i="7287" txt_f="7289">].</offsets></p><p><offsets xml_i="14569" xml_f="14785" txt_i="7290" txt_f="7506">Previously, others demonstrated that physical exercise alters the number and function of leukocytes, including circulating cells of the innate immune system, such as neutrophils, monocytes, and natural killer cells [</offsets><xref rid="B24" ref-type="bibr"><offsets xml_i="14817" xml_f="14819" txt_i="7506" txt_f="7508">24</offsets></xref><offsets xml_i="14826" xml_f="15097" txt_i="7508" txt_f="7779">]. However, the effect of physical exercise on DC is rather unexplored. Increased DC numbers were found following exercise training in an animal model, whereas their phenotype, that is, the expression of the costimulatory molecules CD80 and CD86 by DC, was not affected [</offsets><xref rid="B25" ref-type="bibr"><offsets xml_i="15129" xml_f="15131" txt_i="7779" txt_f="7781">25</offsets></xref><offsets xml_i="15138" xml_f="15276" txt_i="7781" txt_f="7919">]. Interestingly, after 5 weeks of physical exercise, bone marrow-derived rat DC displayed a more pronounced immune-stimulatory function [</offsets><xref rid="B25" ref-type="bibr"><offsets xml_i="15308" xml_f="15310" txt_i="7919" txt_f="7921">25</offsets></xref><offsets xml_i="15317" xml_f="15406" txt_i="7921" txt_f="8010">]. Also in humans, increased numbers of cDC, but not pDC, were found following exercise [</offsets><xref rid="B26" ref-type="bibr"><offsets xml_i="15438" xml_f="15440" txt_i="8010" txt_f="8012">26</offsets></xref><offsets xml_i="15447" xml_f="15449" txt_i="8012" txt_f="8014">, </offsets><xref rid="B27" ref-type="bibr"><offsets xml_i="15481" xml_f="15483" txt_i="8014" txt_f="8016">27</offsets></xref><offsets xml_i="15490" xml_f="15492" txt_i="8016" txt_f="8018">].</offsets></p><p><offsets xml_i="15499" xml_f="16019" txt_i="8019" txt_f="8539">Altogether, it has been demonstrated that physical exercise is well tolerated and induces relevant improvements in both physical and mental functioning of MS patients, although its effect on underlying mechanisms remains to be elucidated. Since recent evidence suggests a crucial role for innate immunity in the initiation as well as progression of MS, we aim to investigate the effect of a 12-week combined endurance and resistance exercise program on cellular and molecular mediators of innate immunity in MS patients.</offsets></p></sec><sec id="sec2"><title><offsets xml_i="16051" xml_f="16074" txt_i="8541" txt_f="8564">2. Material and methods</offsets></title><sec id="sec2.1"><title><offsets xml_i="16106" xml_f="16127" txt_i="8565" txt_f="8586">2.1. Study Population</offsets></title><p><offsets xml_i="16138" xml_f="16219" txt_i="8587" txt_f="8668">A total of 67 MS patients, diagnosed according to the revised McDonald criteria [</offsets><xref rid="B28" ref-type="bibr"><offsets xml_i="16251" xml_f="16253" txt_i="8668" txt_f="8670">28</offsets></xref><offsets xml_i="16260" xml_f="17141" txt_i="8670" txt_f="9545">] and aged &gt;18 years, were assessed for eligibility by the REVAL Rehabilitation Research Centre. Subjects were excluded if they had an expanded disability status scale (EDSS) score &gt;6, that is, not able to walk 100 m without walking aid, physician-diagnosed diabetes mellitus type II, other autoimmune diseases (diabetes mellitus type I and/or rheumatoid arthritis), or other chronic diseases (cardiovascular, pulmonary, and/or renal), were pregnant, participated in another study, had contraindications to perform physical exercise, received corticosteroid treatment 3 months prior to the study, or had an acute MS exacerbation 6 months prior to the study. All subjects gave informed consent in accordance with the declaration of Helsinki and the protocol was approved by the local Ethics Committee of Virga Jesse Hospital, Hasselt, and Hasselt University and registered at </offsets><ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/"><offsets xml_i="17216" xml_f="17247" txt_i="9545" txt_f="9576">https://www.clinicaltrials.gov/</offsets></ext-link><offsets xml_i="17258" xml_f="17260" txt_i="9576" txt_f="9578"> (</offsets><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01718392?term=NCT01718392&amp;rank=1"><offsets xml_i="17379" xml_f="17390" txt_i="9578" txt_f="9589">NCT01718392</offsets></ext-link><offsets xml_i="17401" xml_f="17406" txt_i="9589" txt_f="9594"> and </offsets><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01845896?term=NCT01845896&amp;rank=1"><offsets xml_i="17525" xml_f="17536" txt_i="9594" txt_f="9605">NCT01845896</offsets></ext-link><offsets xml_i="17547" xml_f="17549" txt_i="9605" txt_f="9607">).</offsets></p></sec><sec id="sec2.2"><title><offsets xml_i="17583" xml_f="17600" txt_i="9609" txt_f="9626">2.2. Study Design</offsets></title><p><offsets xml_i="17611" xml_f="17721" txt_i="9627" txt_f="9737">MS patients were randomized by sealed envelope following a 3 : 2 ratio to an exercise intervention group (EX: </offsets><italic><offsets xml_i="17729" xml_f="17730" txt_i="9737" txt_f="9738">n</offsets></italic><offsets xml_i="17739" xml_f="17781" txt_i="9738" txt_f="9780"> = 38) or a sedentary control group (SED: </offsets><italic><offsets xml_i="17789" xml_f="17790" txt_i="9780" txt_f="9781">n</offsets></italic><offsets xml_i="17799" xml_f="17999" txt_i="9781" txt_f="9981"> = 25) by the REVAL Rehabilitation Research Centre. Respectively, only 29 and 16 patients were included in the repeated measures analysis, due to loss to follow-up or discontinuation of intervention (</offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="18031" xml_f="18039" txt_i="9981" txt_f="9989">Figure 1</offsets></xref><offsets xml_i="18046" xml_f="18310" txt_i="9989" txt_f="10253">). The ratio of patients who discontinued the intervention and the ratio of patients who were lost to follow-up were not significantly different between the exercise and the sedentary group (see Supplementary Appendix in Supplementary Material available online at </offsets><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1155/2016/6789276"><offsets xml_i="18392" xml_f="18430" txt_i="10253" txt_f="10291">http://dx.doi.org/10.1155/2016/6789276</offsets></ext-link><offsets xml_i="18441" xml_f="18443" txt_i="10291" txt_f="10293">).</offsets></p><p><offsets xml_i="18450" xml_f="21173" txt_i="10294" txt_f="13017">Patient characteristics and medication use are depicted in Supplementary Table 1. Due to the nature of the trial, patients and caregivers could not be blinded to group allocation, whereas those assessing the outcomes were blinded to group allocation. Patients in the exercise group participated in a supervised 12-week combined endurance and resistance training program in the REVAL Rehabilitation Research Centre at a frequency of 5 sessions per 2 weeks. Each session started with a cardiovascular part, consisting of cycling and treadmill walking or running (Technogym, LJ Capelle aan den Ijssel, The Netherlands). Session duration and intensity increased as the program proceeded, starting from 1 × 6 min/session to 3 × 10 min/session, interspersed by 2-3 minutes of rest. The duration was determined beforehand, whereas the intensity was determined individually depending on heart rate and disability level. For example, participants needed to be able to walk/pedal uninterrupted and independently for the prescribed minutes, and intensity decreased when they had difficulties keeping up with the pace or felt not confident to succeed in the program. The second part consisted of resistance training (leg press, leg curl, leg extension, vertical traction, arm curl, and chest press, Technogym). Resistance training of the lower limb was performed unilaterally, due to bilateral strength differences between the legs of MS patients. To improve muscle fitness, sets of repetitions gradually increased during intervention, from 1 × 10 repetitions to 4 × 15 repetitions, with maximal attainable load, interspersed by 1-2 minutes of rest. The number of repetitions was determined beforehand, whereas the intensity was determined individually, based on individual disability levels, which are inconstant in MS. When the number of repetitions increased, the maximal attainable load decreased. After two or three sessions, working with the same number of repetitions, participants were encouraged to, if possible, increase their weights again. Continuous encouragement and supervision by the instructors during the training period led to a systematic increase of the training load over the 12-week training period. The sessions were finished by stretching. Patients in the sedentary group did not participate in any training program and were asked to continue standard care. Blood (20 mL) was sampled from patients in both groups in fasting state at 8 a.m. following abstinence from exercise for 48 hours. Samples were collected before the combined exercise program (PRE) and within one week after the end of the 12-week training program (POST) in both heparin and serum-separating tubes (BD Biosciences, Erembodegem, Belgium).</offsets></p></sec><sec id="sec2.3"><title><offsets xml_i="21207" xml_f="21251" txt_i="13019" txt_f="13063">2.3. Isolation and Stimulation of Leukocytes</offsets></title><p><offsets xml_i="21262" xml_f="21406" txt_i="13064" txt_f="13208">Leukocyte cell counts were measured using an automated cell counter (ABX Micros 60, Horiba, Deurne, Belgium). Next, leukocytes were isolated for</offsets><italic><offsets xml_i="21414" xml_f="21422" txt_i="13208" txt_f="13216"> ex vivo</offsets></italic><offsets xml_i="21431" xml_f="21714" txt_i="13216" txt_f="13499"> flow cytometric analysis of DC and Treg subsets using density gradient purification (Ficoll Paque PLUS, GE Healthcare, Chalfont St Giles, UK). In addition, for evaluation of Treg frequencies using intracellular flow cytometry, leukocytes were treated overnight with brefeldin A (10 </offsets><italic><offsets xml_i="21722" xml_f="21723" txt_i="13499" txt_f="13500">µ</offsets></italic><offsets xml_i="21732" xml_f="21856" txt_i="13500" txt_f="13624">g/mL) (Life Technologies, Merelbeke, Belgium). Simultaneously, 1 mL of peripheral blood was (i) stimulated overnight with 2 </offsets><italic><offsets xml_i="21864" xml_f="21865" txt_i="13624" txt_f="13625">μ</offsets></italic><offsets xml_i="21874" xml_f="21936" txt_i="13625" txt_f="13687">g/mL LPS, a TLR4 ligand (Invivogen, Toulouse, France), and 50 </offsets><italic><offsets xml_i="21944" xml_f="21945" txt_i="13687" txt_f="13688">µ</offsets></italic><offsets xml_i="21954" xml_f="21963" txt_i="13688" txt_f="13697">g/mL IFN-</offsets><italic><offsets xml_i="21971" xml_f="21972" txt_i="13697" txt_f="13698">γ</offsets></italic><offsets xml_i="21981" xml_f="22054" txt_i="13698" txt_f="13771"> (Immunotools, Friesoythe, Germany) or (ii) stimulated overnight with 10 </offsets><italic><offsets xml_i="22062" xml_f="22063" txt_i="13771" txt_f="13772">μ</offsets></italic><offsets xml_i="22072" xml_f="22408" txt_i="13772" txt_f="14108">g/mL imiquimod (IQ), a synthetic TLR7 ligand (Invivogen) or (iii) left untreated as a control. For evaluation of TLR-mediated cytokine production, plasma was collected and stored at −20°C for further use in cytokine secretion assays. For evaluation of DC activation state, leukocytes were enriched after red blood cell lysis (0.155 M NH</offsets><sub><offsets xml_i="22413" xml_f="22414" txt_i="14108" txt_f="14109">4</offsets></sub><offsets xml_i="22420" xml_f="22435" txt_i="14109" txt_f="14124">Cl, 0.01 M KHCO</offsets><sub><offsets xml_i="22440" xml_f="22441" txt_i="14124" txt_f="14125">3</offsets></sub><offsets xml_i="22447" xml_f="22462" txt_i="14125" txt_f="14140">, and 0.1 mM Na</offsets><sub><offsets xml_i="22467" xml_f="22468" txt_i="14140" txt_f="14141">2</offsets></sub><offsets xml_i="22474" xml_f="22481" txt_i="14141" txt_f="14148">-EDTA).</offsets></p></sec><sec id="sec2.4"><title><offsets xml_i="22515" xml_f="22534" txt_i="14150" txt_f="14169">2.4. Flow Cytometry</offsets></title><p><offsets xml_i="22545" xml_f="23437" txt_i="14170" txt_f="15062">Immunophenotyping of DC was done by direct immunofluorescence staining using the following fluorochrome-labeled mouse anti-human monoclonal antibodies: anti-blood dendritic cell antigen- (BDCA-) 1 phycoerythrin (PE) (Miltenyi Biotec, Leiden, The Netherlands), anti-BDCA-2 allophycocyanin (APC) (Miltenyi Biotec), anti-lineage I (Lin I; anti-CD3, anti-CD14, anti-CD16, anti-CD19, anti-CD20, and anti-CD56) fluorescein isothiocyanate (FITC) (BD Biosciences), anti-CD62L PE-cyanine 7 (PE-Cy7) (eBioscience, Vienna, Austria), anti-CD80 APC-H7 (BD Biosciences), anti-CD86 V450 (BD Biosciences), anti-CCR5 PE-Cy7 (BD Biosciences), anti-CCR7 V450 (BD Biosciences), and anti-human leukocyte antigen- (HLA-) DR APC-H7 (BD Biosciences) antibodies. Moreover, dead cells were excluded by addition of violet live/dead stain (Life Technologies) to the antibody mixture. cDC and pDC were identified as Lin I</offsets><sup><offsets xml_i="23442" xml_f="23443" txt_i="15062" txt_f="15063">−</offsets></sup><offsets xml_i="23449" xml_f="23456" txt_i="15063" txt_f="15070"> BDCA-1</offsets><sup><offsets xml_i="23461" xml_f="23462" txt_i="15070" txt_f="15071">+</offsets></sup><offsets xml_i="23468" xml_f="23478" txt_i="15071" txt_f="15081"> and Lin I</offsets><sup><offsets xml_i="23483" xml_f="23484" txt_i="15081" txt_f="15082">−</offsets></sup><offsets xml_i="23490" xml_f="23497" txt_i="15082" txt_f="15089"> BDCA-2</offsets><sup><offsets xml_i="23502" xml_f="23503" txt_i="15089" txt_f="15090">+</offsets></sup><offsets xml_i="23509" xml_f="23739" txt_i="15090" txt_f="15320">, respectively. The number of DC displaying an activated or a migratory phenotype was assessed by enumerating cDC and pDC expressing costimulatory molecules (CD80, CD86) and migration markers (CD62L, CCR5, and CCR7), respectively.</offsets></p><p><offsets xml_i="23746" xml_f="24126" txt_i="15321" txt_f="15701">Treg subsets were characterized using the following fluorochrome-labeled mouse anti-human monoclonal antibodies: anti-CD3 peridinin chlorophyll protein Cy5.5 (PerCP-Cy5.5) (BD Biosciences), anti-CD4 APC-H7 (BD Biosciences), anti-CD8 pacific blue (PB) (Life Technologies), anti-CD25 PE-Cy7 (BD Biosciences), anti-IL-10 APC (BD Biosciences), anti-transforming growth factor- (TGF-) </offsets><italic><offsets xml_i="24134" xml_f="24135" txt_i="15701" txt_f="15702">β</offsets></italic><offsets xml_i="24144" xml_f="24424" txt_i="15702" txt_f="15982"> PE (IQ Products, Groningen, The Netherlands), and anti-forkhead box P3 (FoxP3) Alexa Fluor 488 (BD Biosciences). Moreover, dead cells were excluded by addition of violet live/dead stain (Life Technologies) to the antibody mixture. Naturally occurring Treg were identified as CD25</offsets><sup><offsets xml_i="24429" xml_f="24431" txt_i="15982" txt_f="15984">hi</offsets></sup><offsets xml_i="24437" xml_f="24442" txt_i="15984" txt_f="15989">FoxP3</offsets><sup><offsets xml_i="24447" xml_f="24448" txt_i="15989" txt_f="15990">+</offsets></sup><offsets xml_i="24454" xml_f="24635" txt_i="15990" txt_f="16171">, while induced Treg, that is, regulatory type 1 cells (Tr1) and T helper 3 (Th3) cells, were characterized based on the production of the anti-inflammatory cytokines IL-10 and TGF-</offsets><italic><offsets xml_i="24643" xml_f="24644" txt_i="16171" txt_f="16172">β</offsets></italic><offsets xml_i="24653" xml_f="24668" txt_i="16172" txt_f="16187">, respectively.</offsets></p><p><offsets xml_i="24675" xml_f="24820" txt_i="16188" txt_f="16333">Fluorescence minus one in combination with nonreactive isotype-matched antibodies was used as control. For analytical flow cytometry, at least 10</offsets><sup><offsets xml_i="24825" xml_f="24826" txt_i="16333" txt_f="16334">5</offsets></sup><offsets xml_i="24832" xml_f="25091" txt_i="16334" txt_f="16593"> events were measured using a three-laser instrument configured to measure up to 15 parameters simultaneously, that is, a Cyflow ML flow cytometer (Partec, Münster, Germany). All results were analyzed using FlowJo software (Tree Star, Inc., Ashland, OR, USA).</offsets></p></sec><sec id="sec2.5"><title><offsets xml_i="25125" xml_f="25162" txt_i="16595" txt_f="16632">2.5. Soluble Analyte Secretion Assays</offsets></title><p><offsets xml_i="25173" xml_f="25798" txt_i="16633" txt_f="17258">Serum was isolated using serum-separating tubes (BD Biosciences). Quantitative detection of cortisol (Alpco, Salem, NH, USA) and dehydroepiandrosterone (DHEA; Alpco), was determined by means of ELISA according to manufacturer's instructions. Levels of the primary human anti-inflammatory glucocorticoid, cortisol, are often insufficient to evaluate the function of the hypothalamus-pituitary-adrenal (HPA) axis. Therefore, we also quantified the serum concentration of DHEA, a precursor of the sex hormones testosterone and estrogen and a glucocorticoid antagonist, in order to calculate the molar ratio of cortisol to DHEA [</offsets><xref rid="B29" ref-type="bibr"><offsets xml_i="25830" xml_f="25832" txt_i="17258" txt_f="17260">29</offsets></xref><offsets xml_i="25839" xml_f="25841" txt_i="17260" txt_f="17262">, </offsets><xref rid="B30" ref-type="bibr"><offsets xml_i="25873" xml_f="25875" txt_i="17262" txt_f="17264">30</offsets></xref><offsets xml_i="25882" xml_f="25941" txt_i="17264" txt_f="17323">]. In addition, serum levels of IL-6, IL-10, IL-12p70, TNF-</offsets><italic><offsets xml_i="25949" xml_f="25950" txt_i="17323" txt_f="17324">α</offsets></italic><offsets xml_i="25959" xml_f="26415" txt_i="17324" txt_f="17776">, MMP-9, and the inflammasome effector molecule caspase-1 (R&amp;D, Minneapolis, MN, USA) were quantified using ELISA according to manufacturer's instructions. All kits were purchased from Meso Scale Discovery (MSD, Rockville, MD, USA), unless stated otherwise. For quantitative detection of the cytokines secreted following stimulation of peripheral blood, collected plasma samples were analyzed using the following commercially available ELISA kits: IL-1</offsets><italic><offsets xml_i="26423" xml_f="26424" txt_i="17776" txt_f="17777">β</offsets></italic><offsets xml_i="26433" xml_f="26455" txt_i="17777" txt_f="17799">, IL-6, IL-12p70, TNF-</offsets><italic><offsets xml_i="26463" xml_f="26464" txt_i="17799" txt_f="17800">α</offsets></italic><offsets xml_i="26473" xml_f="26479" txt_i="17800" txt_f="17806">, IFN-</offsets><italic><offsets xml_i="26487" xml_f="26488" txt_i="17806" txt_f="17807">α</offsets></italic><offsets xml_i="26497" xml_f="26683" txt_i="17807" txt_f="17989"> (PBL InterferonSource, Piscataway, NJ, USA), caspase-1 (R&amp;D), and MMP-9, according to manufacturer's instructions. All kits were purchased from eBioscience, unless stated otherwise.</offsets></p></sec><sec id="sec2.6"><title><offsets xml_i="26717" xml_f="26742" txt_i="17991" txt_f="18016">2.6. Statistical Analysis</offsets></title><p><offsets xml_i="26753" xml_f="26897" txt_i="18017" txt_f="18161">All data were analyzed using SAS 9.3 software (SAS Institute Inc., Cary, USA). Linear mixed models were used to analyze repeated measures data [</offsets><xref rid="B31" ref-type="bibr"><offsets xml_i="26929" xml_f="26931" txt_i="18161" txt_f="18163">31</offsets></xref><offsets xml_i="26938" xml_f="27514" txt_i="18163" txt_f="18739">]. A model was built stepwise per outcome variable, starting from a univariate model with “time” as the only fixed effect. Step by step new models were constructed by adding other fixed effect variables including group, MS type, gender, age, body mass index (BMI), EDSS, and MS-specific medication. The variable “group” included trained (EX) and sedentary MS patients (SED). The variable “MS type” included relapsing-remitting (RR) and chronic-progressive (CP) MS patients. The variable “MS-specific medication” included untreated 1st-line treatment and 2nd-line treatment. A </offsets><italic><offsets xml_i="27522" xml_f="27523" txt_i="18739" txt_f="18740">P</offsets></italic><offsets xml_i="27532" xml_f="27550" txt_i="18740" txt_f="18755"> value &lt; 0.10 (</offsets><italic><offsets xml_i="27558" xml_f="27559" txt_i="18755" txt_f="18756">F</offsets></italic><offsets xml_i="27568" xml_f="27840" txt_i="18756" txt_f="19028"> test) was used as the threshold for retaining a fixed effect during model building to decrease the chance of missing a significant effect in the final model. Subsequently, possible interaction effects between the retained fixed effects were assessed and also retained if </offsets><italic><offsets xml_i="27848" xml_f="27849" txt_i="19028" txt_f="19029">P</offsets></italic><offsets xml_i="27858" xml_f="27984" txt_i="19029" txt_f="19152"> &lt; 0.10. For interpretation of the fixed effects in the final model, the threshold for statistical significance was set at </offsets><italic><offsets xml_i="27992" xml_f="27993" txt_i="19152" txt_f="19153">P</offsets></italic><offsets xml_i="28002" xml_f="29096" txt_i="19153" txt_f="20244"> &lt; 0.05. Since we aim to focus on temporal effects, we only report main and interaction effects of time. Furthermore, since our main interest is the effect of time, we did not include baseline measurements of patients who did not complete the study, that is, patients who were lost to follow-up or patients who discontinued the intervention. No bias was expected for excluding baseline measurements from patients who did not complete the study (Supplementary Appendix). Nevertheless, to determine safety of the intervention, patients who relapsed during the study were noted and the annualized relapse rate was calculated for both groups. Models consisting of more than 12 parameters were not interpreted because of the risk of overfitting. With significant interaction effects of time, post hoc analyses were performed using the Bonferroni correction to correct for multiple testing. Moreover, based on our a priori hypotheses that an effect of time, that is, the 12-week exercise intervention, could be observed in the trained group of patients and not in the sedentary group of patients [</offsets><xref rid="B24" ref-type="bibr"><offsets xml_i="29128" xml_f="29130" txt_i="20244" txt_f="20246">24</offsets></xref><offsets xml_i="29137" xml_f="29853" txt_i="20246" txt_f="20962">], post hoc analyses for evaluating the effect of time in both the trained and the sedentary group were always performed, thereby reducing the chance of false negative results. Moreover, we used the conservative Bonferroni correction to account for multiple testing, thereby reducing the chance of detecting false positive results (Supplementary Appendix). Diagnostics were based on the studentized residuals and response variables were log-transformed when necessary. Finally, relevant correlations were assessed using Pearson's correlation test. Graphs were generated in SAS 9.3 software and GraphPad version 5 software (Prism, La Jolla, CA, USA). All data are presented as mean ± standard error of the mean (SEM).</offsets></p></sec></sec><sec id="sec3"><title><offsets xml_i="29891" xml_f="29901" txt_i="20965" txt_f="20975">3. Results</offsets></title><sec id="sec3.1"><title><offsets xml_i="29933" xml_f="30003" txt_i="20976" txt_f="21046">3.1. No Baseline Differences between Trained and Sedentary MS Patients</offsets></title><p><offsets xml_i="30014" xml_f="30105" txt_i="21047" txt_f="21138">MS patients were randomized following a 3 : 2 ratio to an exercise intervention group (EX: </offsets><italic><offsets xml_i="30113" xml_f="30114" txt_i="21138" txt_f="21139">n</offsets></italic><offsets xml_i="30123" xml_f="30165" txt_i="21139" txt_f="21181"> = 38) or a sedentary control group (SED: </offsets><italic><offsets xml_i="30173" xml_f="30174" txt_i="21181" txt_f="21182">n</offsets></italic><offsets xml_i="30183" xml_f="30484" txt_i="21182" txt_f="21483"> = 25). Patients in the exercise group reached a mean adherence percentage of 90%, ranging from 80 to 100%, at the end of the 12-week training program. At the end of the study, all data points from 29 and 16 patients in the exercise and the sedentary group, respectively, were collected for analysis (</offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="30516" xml_f="30524" txt_i="21483" txt_f="21491">Figure 1</offsets></xref><offsets xml_i="30531" xml_f="30753" txt_i="21491" txt_f="21713">), changing the ratio to 2 : 1. No differences in the distribution of gender, age, BMI, clinical course of MS, EDSS, and use of MS-specific medication could be detected for the analyzed patients between both study groups (</offsets><xref ref-type="table" rid="tab1"><offsets xml_i="30787" xml_f="30794" txt_i="21713" txt_f="21720">Table 1</offsets></xref><offsets xml_i="30801" xml_f="30985" txt_i="21720" txt_f="21904">). Similarly, no differences at baseline could be detected for all experimental outcomes tested between the exercise group and the sedentary control group except for the number of CCR5</offsets><sup><offsets xml_i="30990" xml_f="30991" txt_i="21904" txt_f="21905">+</offsets></sup><offsets xml_i="30997" xml_f="31003" txt_i="21905" txt_f="21911"> cDC (</offsets><italic><offsets xml_i="31011" xml_f="31012" txt_i="21911" txt_f="21912">P</offsets></italic><offsets xml_i="31021" xml_f="31072" txt_i="21912" txt_f="21963"> = 0.033), which was higher in the exercise group (</offsets><italic><offsets xml_i="31080" xml_f="31090" txt_i="21963" txt_f="21973">vide infra</offsets></italic><offsets xml_i="31099" xml_f="31101" txt_i="21973" txt_f="21975">).</offsets></p></sec><sec id="sec3.2"><title><offsets xml_i="31135" xml_f="31239" txt_i="21977" txt_f="22081">3.2. Serum Signaling Molecule Concentrations Are Not Altered following Long-Term Physical Exercise in MS</offsets></title><p><offsets xml_i="31250" xml_f="31496" txt_i="22082" txt_f="22328">Although no difference in the cortisol concentration between the patient groups in the course of the 12-week time period could be detected, cortisol levels significantly increased in the trained group after the 12-week combined exercise program (</offsets><italic><offsets xml_i="31504" xml_f="31505" txt_i="22328" txt_f="22329">P</offsets></italic><offsets xml_i="31514" xml_f="31524" txt_i="22329" txt_f="22339"> = 0.047, </offsets><xref ref-type="table" rid="tab2"><offsets xml_i="31558" xml_f="31565" txt_i="22339" txt_f="22346">Table 2</offsets></xref><offsets xml_i="31572" xml_f="32124" txt_i="22346" txt_f="22898">), while no change was observed in the sedentary control group. However, the physiological relevance of this relatively small increase (fold increase = 1.07) is debatable. No significant differences of the concentration of DHEA and the molar concentration of cortisol to DHEA could be detected following the 12-week time period between the exercise group and the sedentary control group. In our hands, no significant differences could be detected between the exercise group and the sedentary control group in the course of the 12-week time period with </offsets><italic><offsets xml_i="32132" xml_f="32133" txt_i="22898" txt_f="22899">α</offsets></italic><offsets xml_i="32142" xml_f="32166" txt_i="22899" txt_f="22923">, caspase-1, and MMP-9 (</offsets><xref ref-type="table" rid="tab2"><offsets xml_i="32200" xml_f="32207" txt_i="22923" txt_f="22930">Table 2</offsets></xref><offsets xml_i="32214" xml_f="32216" txt_i="22930" txt_f="22932">).</offsets></p></sec><sec id="sec3.3"><title><offsets xml_i="32250" xml_f="32331" txt_i="22934" txt_f="23015">3.3. Circulating pDC Numbers Increase following Long-Term Physical Exercise in MS</offsets></title><p><offsets xml_i="32342" xml_f="32693" txt_i="23016" txt_f="23367">We were not able to detect an effect of the physical exercise program on the absolute number of total leukocytes nor on the absolute number of lymphocytes, monocytes, and granulocytes (data not shown). Next, we investigated the number of circulating DC subsets, that is, cDC and pDC, in MS patients participating in the combined exercise program (EX, </offsets><italic><offsets xml_i="32701" xml_f="32702" txt_i="23367" txt_f="23368">n</offsets></italic><offsets xml_i="32711" xml_f="32766" txt_i="23368" txt_f="23423"> = 29) as compared to sedentary control patients (SED, </offsets><italic><offsets xml_i="32774" xml_f="32775" txt_i="23423" txt_f="23424">n</offsets></italic><offsets xml_i="32784" xml_f="32977" txt_i="23424" txt_f="23617"> = 16). Our findings demonstrate that, in the course of the 12-week time period, a difference between trained and sedentary patients could be demonstrated regarding the absolute number of pDC (</offsets><italic><offsets xml_i="32985" xml_f="32986" txt_i="23617" txt_f="23618">P</offsets></italic><offsets xml_i="32995" xml_f="33080" txt_i="23618" txt_f="23703"> = 0.017). Indeed, increased cell counts of pDC were detected in the exercise group (</offsets><italic><offsets xml_i="33088" xml_f="33089" txt_i="23703" txt_f="23704">P</offsets></italic><offsets xml_i="33098" xml_f="33108" txt_i="23704" txt_f="23714"> = 0.010; </offsets><xref ref-type="fig" rid="fig2"><offsets xml_i="33140" xml_f="33151" txt_i="23714" txt_f="23725">Figure 2(a)</offsets></xref><offsets xml_i="33158" xml_f="33380" txt_i="23725" txt_f="23947">) after 12 weeks, while no changes were observed in the sedentary control group. Also the proportion of circulating pDC within total white blood cells was increased in MS patients who participated in the exercise program (</offsets><italic><offsets xml_i="33388" xml_f="33389" txt_i="23947" txt_f="23948">P</offsets></italic><offsets xml_i="33398" xml_f="33604" txt_i="23948" txt_f="24154"> = 0.050; data not shown). No effect of the 12-week intervention on the absolute number of cDC could be detected. Both patient groups displayed an increase in the absolute number of cDC after 12 weeks (EX: </offsets><italic><offsets xml_i="33612" xml_f="33613" txt_i="24154" txt_f="24155">P</offsets></italic><offsets xml_i="33622" xml_f="33637" txt_i="24155" txt_f="24170"> = 0.026, SED: </offsets><italic><offsets xml_i="33645" xml_f="33646" txt_i="24170" txt_f="24171">P</offsets></italic><offsets xml_i="33655" xml_f="33665" txt_i="24171" txt_f="24181"> = 0.002; </offsets><xref ref-type="fig" rid="fig2"><offsets xml_i="33697" xml_f="33708" txt_i="24181" txt_f="24192">Figure 2(b)</offsets></xref><offsets xml_i="33715" xml_f="33717" txt_i="24192" txt_f="24194">).</offsets></p></sec><sec id="sec3.4"><title><offsets xml_i="33751" xml_f="33864" txt_i="24196" txt_f="24309">3.4. Increased Numbers of pDC with an Activated Phenotype Are Found following the Physical Exercise Program in MS</offsets></title><p><offsets xml_i="33875" xml_f="34123" txt_i="24310" txt_f="24558">The absolute number of cDC and pDC positive for the costimulatory molecules CD80 and CD86 was analyzed by flow cytometry. In the course of the 12-week time period, a difference was observed between the patient groups for the absolute number of CD80</offsets><sup><offsets xml_i="34128" xml_f="34129" txt_i="24558" txt_f="24559">+</offsets></sup><offsets xml_i="34135" xml_f="34141" txt_i="24559" txt_f="24565"> pDC (</offsets><italic><offsets xml_i="34149" xml_f="34150" txt_i="24565" txt_f="24566">P</offsets></italic><offsets xml_i="34159" xml_f="34180" txt_i="24566" txt_f="24587"> = 0.015) and of CD86</offsets><sup><offsets xml_i="34185" xml_f="34186" txt_i="24587" txt_f="24588">+</offsets></sup><offsets xml_i="34192" xml_f="34198" txt_i="24588" txt_f="24594"> pDC (</offsets><italic><offsets xml_i="34206" xml_f="34207" txt_i="24594" txt_f="24595">P</offsets></italic><offsets xml_i="34216" xml_f="34274" txt_i="24595" txt_f="24653"> = 0.016). Indeed, significantly increased numbers of CD80</offsets><sup><offsets xml_i="34279" xml_f="34280" txt_i="24653" txt_f="24654">+</offsets></sup><offsets xml_i="34286" xml_f="34369" txt_i="24654" txt_f="24737"> pDC were observed in MS patients following the 12-week combined exercise program (</offsets><italic><offsets xml_i="34377" xml_f="34378" txt_i="24737" txt_f="24738">P</offsets></italic><offsets xml_i="34387" xml_f="34400" txt_i="24738" txt_f="24748"> &lt; 0.001; </offsets><xref ref-type="fig" rid="fig2"><offsets xml_i="34432" xml_f="34443" txt_i="24748" txt_f="24759">Figure 2(c)</offsets></xref><offsets xml_i="34450" xml_f="34495" txt_i="24759" txt_f="24804">), while no differences in the number of CD80</offsets><sup><offsets xml_i="34500" xml_f="34501" txt_i="24804" txt_f="24805">+</offsets></sup><offsets xml_i="34507" xml_f="34609" txt_i="24805" txt_f="24907"> pDC could be found in the sedentary control group. Similarly, also the proportion of circulating CD80</offsets><sup><offsets xml_i="34614" xml_f="34615" txt_i="24907" txt_f="24908">+</offsets></sup><offsets xml_i="34621" xml_f="34728" txt_i="24908" txt_f="25015"> pDC within total white blood cells was increased in MS patients who participated in the exercise program (</offsets><italic><offsets xml_i="34736" xml_f="34737" txt_i="25015" txt_f="25016">P</offsets></italic><offsets xml_i="34746" xml_f="34834" txt_i="25016" txt_f="25104"> = 0.030; data not shown). Both intervention groups display, however, a decrease in CD86</offsets><sup><offsets xml_i="34839" xml_f="34840" txt_i="25104" txt_f="25105">+</offsets></sup><offsets xml_i="34846" xml_f="34879" txt_i="25105" txt_f="25138"> pDC numbers after 12 weeks (EX: </offsets><italic><offsets xml_i="34887" xml_f="34888" txt_i="25138" txt_f="25139">P</offsets></italic><offsets xml_i="34897" xml_f="34912" txt_i="25139" txt_f="25154"> = 0.046, SED: </offsets><italic><offsets xml_i="34920" xml_f="34921" txt_i="25154" txt_f="25155">P</offsets></italic><offsets xml_i="34930" xml_f="34940" txt_i="25155" txt_f="25165"> = 0.001; </offsets><xref ref-type="fig" rid="fig2"><offsets xml_i="34972" xml_f="34983" txt_i="25165" txt_f="25176">Figure 2(c)</offsets></xref><offsets xml_i="34990" xml_f="35222" txt_i="25176" txt_f="25408">), indicative of an effect that cannot be attributed to the physical exercise program. In addition, no differences in the course of the 12-week time period could be detected between the patient groups for the absolute number of CD80</offsets><sup><offsets xml_i="35227" xml_f="35228" txt_i="25408" txt_f="25409">+</offsets></sup><offsets xml_i="35234" xml_f="35243" txt_i="25409" txt_f="25418"> and CD86</offsets><sup><offsets xml_i="35248" xml_f="35249" txt_i="25418" txt_f="25419">+</offsets></sup><offsets xml_i="35255" xml_f="35274" txt_i="25419" txt_f="25438"> cDC, although CD86</offsets><sup><offsets xml_i="35279" xml_f="35280" txt_i="25438" txt_f="25439">+</offsets></sup><offsets xml_i="35286" xml_f="35362" txt_i="25439" txt_f="25515"> cDC significantly decreased after 12 weeks in the sedentary control group (</offsets><italic><offsets xml_i="35370" xml_f="35371" txt_i="25515" txt_f="25516">P</offsets></italic><offsets xml_i="35380" xml_f="35390" txt_i="25516" txt_f="25526"> = 0.022; </offsets><xref ref-type="fig" rid="fig2"><offsets xml_i="35422" xml_f="35433" txt_i="25526" txt_f="25537">Figure 2(d)</offsets></xref><offsets xml_i="35440" xml_f="35442" txt_i="25537" txt_f="25539">).</offsets></p><p><offsets xml_i="35449" xml_f="35626" txt_i="25540" txt_f="25717">Simultaneously, the absolute number of cDC and pDC positive for the migration markers, CD62L, CCR5, and CCR7, was measured. No differences regarding the absolute number of CD62L</offsets><sup><offsets xml_i="35631" xml_f="35632" txt_i="25717" txt_f="25718">+</offsets></sup><offsets xml_i="35638" xml_f="35644" txt_i="25718" txt_f="25724">, CCR5</offsets><sup><offsets xml_i="35649" xml_f="35650" txt_i="25724" txt_f="25725">+</offsets></sup><offsets xml_i="35656" xml_f="35666" txt_i="25725" txt_f="25735">, and CCR7</offsets><sup><offsets xml_i="35671" xml_f="35672" txt_i="25735" txt_f="25736">+</offsets></sup><offsets xml_i="35678" xml_f="35828" txt_i="25736" txt_f="25886"> pDC were detected between the patient groups in the course of the 12-week time period. However, we did show a significantly increased number of CD62L</offsets><sup><offsets xml_i="35833" xml_f="35834" txt_i="25886" txt_f="25887">+</offsets></sup><offsets xml_i="35840" xml_f="35892" txt_i="25887" txt_f="25939"> pDC in MS patients following the exercise program (</offsets><italic><offsets xml_i="35900" xml_f="35901" txt_i="25939" txt_f="25940">P</offsets></italic><offsets xml_i="35910" xml_f="35920" txt_i="25940" txt_f="25950"> = 0.002; </offsets><xref ref-type="fig" rid="fig2"><offsets xml_i="35952" xml_f="35963" txt_i="25950" txt_f="25961">Figure 2(e)</offsets></xref><offsets xml_i="35970" xml_f="36104" txt_i="25961" txt_f="26095">), while no changes were observed in the sedentary control group. In addition, a modest but significant decrease in the number of CCR7</offsets><sup><offsets xml_i="36109" xml_f="36110" txt_i="26095" txt_f="26096">+</offsets></sup><offsets xml_i="36116" xml_f="36186" txt_i="26096" txt_f="26166"> pDC could be detected after 12 weeks in the sedentary control group (</offsets><italic><offsets xml_i="36194" xml_f="36195" txt_i="26166" txt_f="26167">P</offsets></italic><offsets xml_i="36204" xml_f="36214" txt_i="26167" txt_f="26177"> = 0.009; </offsets><xref ref-type="fig" rid="fig2"><offsets xml_i="36246" xml_f="36257" txt_i="26177" txt_f="26188">Figure 2(e)</offsets></xref><offsets xml_i="36264" xml_f="36320" txt_i="26188" txt_f="26244">). No differences regarding the absolute number of CD62L</offsets><sup><offsets xml_i="36325" xml_f="36326" txt_i="26244" txt_f="26245">+</offsets></sup><offsets xml_i="36332" xml_f="36338" txt_i="26245" txt_f="26251">, CCR5</offsets><sup><offsets xml_i="36343" xml_f="36344" txt_i="26251" txt_f="26252">+</offsets></sup><offsets xml_i="36350" xml_f="36360" txt_i="26252" txt_f="26262">, and CCR7</offsets><sup><offsets xml_i="36365" xml_f="36366" txt_i="26262" txt_f="26263">+</offsets></sup><offsets xml_i="36372" xml_f="36518" txt_i="26263" txt_f="26409"> cDC could be detected between the groups in the course of the 12-week time period, although modest but significant changes in the number of CD62L</offsets><sup><offsets xml_i="36523" xml_f="36524" txt_i="26409" txt_f="26410">+</offsets></sup><offsets xml_i="36530" xml_f="36539" txt_i="26410" txt_f="26419"> and CCR5</offsets><sup><offsets xml_i="36544" xml_f="36545" txt_i="26419" txt_f="26420">+</offsets></sup><offsets xml_i="36551" xml_f="36613" txt_i="26420" txt_f="26482"> cDC could be observed in the sedentary control group (CD62L: </offsets><italic><offsets xml_i="36621" xml_f="36622" txt_i="26482" txt_f="26483">P</offsets></italic><offsets xml_i="36631" xml_f="36647" txt_i="26483" txt_f="26499"> = 0.041, CCR5: </offsets><italic><offsets xml_i="36655" xml_f="36656" txt_i="26499" txt_f="26500">P</offsets></italic><offsets xml_i="36665" xml_f="36675" txt_i="26500" txt_f="26510"> = 0.025; </offsets><xref ref-type="fig" rid="fig2"><offsets xml_i="36707" xml_f="36718" txt_i="26510" txt_f="26521">Figure 2(f)</offsets></xref><offsets xml_i="36725" xml_f="36727" txt_i="26521" txt_f="26523">).</offsets></p><p><offsets xml_i="36734" xml_f="36802" txt_i="26524" txt_f="26592">Taken together, our observations show that increased numbers of CD80</offsets><sup><offsets xml_i="36807" xml_f="36808" txt_i="26592" txt_f="26593">+</offsets></sup><offsets xml_i="36814" xml_f="36824" txt_i="26593" txt_f="26603"> and CD62L</offsets><sup><offsets xml_i="36829" xml_f="36830" txt_i="26603" txt_f="26604">+</offsets></sup><offsets xml_i="36836" xml_f="36921" txt_i="26604" txt_f="26689"> pDC, indicative of an activated phenotype, are found following the exercise program.</offsets></p></sec><sec id="sec3.5"><title><offsets xml_i="36955" xml_f="37033" txt_i="26691" txt_f="26769">3.5. TLR Responsiveness following Long-Term Physical Exercise in MS Is Altered</offsets></title><p><offsets xml_i="37044" xml_f="37197" txt_i="26770" txt_f="26923">In order to assess the responsiveness of circulating DC to danger signals, blood samples were stimulated with a TLR4 ligand, LPS in combination with IFN-</offsets><italic><offsets xml_i="37205" xml_f="37206" txt_i="26923" txt_f="26924">γ</offsets></italic><offsets xml_i="37215" xml_f="37301" txt_i="26924" txt_f="27010">, or a TLR7 ligand, IQ. Both ligands are known to activate cDC and pDC, respectively [</offsets><xref rid="B32" ref-type="bibr"><offsets xml_i="37333" xml_f="37335" txt_i="27010" txt_f="27012">32</offsets></xref><offsets xml_i="37342" xml_f="37344" txt_i="27012" txt_f="27014">, </offsets><xref rid="B33" ref-type="bibr"><offsets xml_i="37376" xml_f="37378" txt_i="27014" txt_f="27016">33</offsets></xref><offsets xml_i="37385" xml_f="37443" txt_i="27016" txt_f="27074">]. Following 12 weeks of exercise, the fold change of CCR5</offsets><sup><offsets xml_i="37448" xml_f="37449" txt_i="27074" txt_f="27075">+</offsets></sup><offsets xml_i="37455" xml_f="37477" txt_i="27075" txt_f="27097"> cDC upon LPS and IFN-</offsets><italic><offsets xml_i="37485" xml_f="37486" txt_i="27097" txt_f="27098">γ</offsets></italic><offsets xml_i="37495" xml_f="37545" txt_i="27098" txt_f="27148"> stimulation was decreased in the exercise group (</offsets><italic><offsets xml_i="37553" xml_f="37554" txt_i="27148" txt_f="27149">P</offsets></italic><offsets xml_i="37563" xml_f="37573" txt_i="27149" txt_f="27159"> = 0.002; </offsets><xref ref-type="table" rid="tab3"><offsets xml_i="37607" xml_f="37614" txt_i="27159" txt_f="27166">Table 3</offsets></xref><offsets xml_i="37621" xml_f="37717" txt_i="27166" txt_f="27262">) and significantly differed from the sedentary group in the course of the 12-week time period (</offsets><italic><offsets xml_i="37725" xml_f="37726" txt_i="27262" txt_f="27263">P</offsets></italic><offsets xml_i="37735" xml_f="37807" txt_i="27263" txt_f="27335"> = 0.038), where no changes were observed. No differences regarding TNF-</offsets><italic><offsets xml_i="37815" xml_f="37816" txt_i="27335" txt_f="27336">α</offsets></italic><offsets xml_i="37825" xml_f="37863" txt_i="27336" txt_f="27374"> and MMP-9 secretion upon LPS and IFN-</offsets><italic><offsets xml_i="37871" xml_f="37872" txt_i="27374" txt_f="27375">γ</offsets></italic><offsets xml_i="37881" xml_f="37999" txt_i="27375" txt_f="27493"> stimulation could be detected between the patient groups in the course of the 12-week time period. Nevertheless, TNF-</offsets><italic><offsets xml_i="38007" xml_f="38008" txt_i="27493" txt_f="27494">α</offsets></italic><offsets xml_i="38017" xml_f="38094" txt_i="27494" txt_f="27571"> and MMP-9 secretion was significantly decreased in trained MS patients (TNF-</offsets><italic><offsets xml_i="38102" xml_f="38103" txt_i="27571" txt_f="27572">α</offsets></italic><offsets xml_i="38112" xml_f="38114" txt_i="27572" txt_f="27574">: </offsets><italic><offsets xml_i="38122" xml_f="38123" txt_i="27574" txt_f="27575">P</offsets></italic><offsets xml_i="38132" xml_f="38149" txt_i="27575" txt_f="27592"> = 0.028; MMP-9: </offsets><italic><offsets xml_i="38157" xml_f="38158" txt_i="27592" txt_f="27593">P</offsets></italic><offsets xml_i="38167" xml_f="38241" txt_i="27593" txt_f="27667"> = 0.040), while no changes were detected in the sedentary control group (</offsets><xref ref-type="table" rid="tab4"><offsets xml_i="38275" xml_f="38282" txt_i="27667" txt_f="27674">Table 4</offsets></xref><offsets xml_i="38289" xml_f="38377" txt_i="27674" txt_f="27762">). In addition, no significant differences could be detected for the fold change of CD86</offsets><sup><offsets xml_i="38382" xml_f="38383" txt_i="27762" txt_f="27763">+</offsets></sup><offsets xml_i="38389" xml_f="38400" txt_i="27763" txt_f="27774"> and HLA-DR</offsets><sup><offsets xml_i="38405" xml_f="38406" txt_i="27774" txt_f="27775">+</offsets></sup><offsets xml_i="38412" xml_f="38457" txt_i="27775" txt_f="27820"> cDC, neither for the secreted amount of IL-1</offsets><italic><offsets xml_i="38465" xml_f="38466" txt_i="27820" txt_f="27821">β</offsets></italic><offsets xml_i="38475" xml_f="38497" txt_i="27821" txt_f="27843">, IL-6, IL-12p70, IFN-</offsets><italic><offsets xml_i="38505" xml_f="38506" txt_i="27843" txt_f="27844">α</offsets></italic><offsets xml_i="38515" xml_f="38548" txt_i="27844" txt_f="27877">, and caspase-1 upon LPS and IFN-</offsets><italic><offsets xml_i="38556" xml_f="38557" txt_i="27877" txt_f="27878">γ</offsets></italic><offsets xml_i="38566" xml_f="38648" txt_i="27878" txt_f="27960"> stimulation between the trained and sedentary MS patients after 12 weeks (Tables </offsets><xref ref-type="table" rid="tab3"><offsets xml_i="38682" xml_f="38683" txt_i="27960" txt_f="27961">3</offsets></xref><offsets xml_i="38690" xml_f="38695" txt_i="27961" txt_f="27966"> and </offsets><xref ref-type="table" rid="tab4"><offsets xml_i="38729" xml_f="38730" txt_i="27966" txt_f="27967">4</offsets></xref><offsets xml_i="38737" xml_f="38739" txt_i="27967" txt_f="27969">).</offsets></p><p><offsets xml_i="38746" xml_f="38813" txt_i="27970" txt_f="28037">In the course of the 12-week time period, the fold change of HLA-DR</offsets><sup><offsets xml_i="38818" xml_f="38819" txt_i="28037" txt_f="28038">+</offsets></sup><offsets xml_i="38825" xml_f="38901" txt_i="28038" txt_f="28114"> pDC upon IQ stimulation differed significantly between the patient groups (</offsets><italic><offsets xml_i="38909" xml_f="38910" txt_i="28114" txt_f="28115">P</offsets></italic><offsets xml_i="38919" xml_f="38981" txt_i="28115" txt_f="28177"> = 0.023). A significant increase in the fold change of HLA-DR</offsets><sup><offsets xml_i="38986" xml_f="38987" txt_i="28177" txt_f="28178">+</offsets></sup><offsets xml_i="38993" xml_f="39074" txt_i="28178" txt_f="28259"> pDC upon IQ stimulation was observed in MS patients after 12 weeks of exercise (</offsets><italic><offsets xml_i="39082" xml_f="39083" txt_i="28259" txt_f="28260">P</offsets></italic><offsets xml_i="39092" xml_f="39143" txt_i="28260" txt_f="28311"> = 0.008), but not in the sedentary control group (</offsets><xref ref-type="table" rid="tab3"><offsets xml_i="39177" xml_f="39184" txt_i="28311" txt_f="28318">Table 3</offsets></xref><offsets xml_i="39191" xml_f="39211" txt_i="28318" txt_f="28338">). Furthermore, IL-1</offsets><italic><offsets xml_i="39219" xml_f="39220" txt_i="28338" txt_f="28339">β</offsets></italic><offsets xml_i="39229" xml_f="39338" txt_i="28339" txt_f="28448"> secretion upon IQ stimulation differed between the patient groups in the course of the 12-week time period (</offsets><italic><offsets xml_i="39346" xml_f="39347" txt_i="28448" txt_f="28449">P</offsets></italic><offsets xml_i="39356" xml_f="39366" txt_i="28449" txt_f="28459"> = 0.039, </offsets><xref ref-type="table" rid="tab4"><offsets xml_i="39400" xml_f="39407" txt_i="28459" txt_f="28466">Table 4</offsets></xref><offsets xml_i="39414" xml_f="39451" txt_i="28466" txt_f="28503">). Nevertheless, after 12 weeks, IL-1</offsets><italic><offsets xml_i="39459" xml_f="39460" txt_i="28503" txt_f="28504">β</offsets></italic><offsets xml_i="39469" xml_f="39545" txt_i="28504" txt_f="28580"> secretion was only significantly decreased in the sedentary control group (</offsets><italic><offsets xml_i="39553" xml_f="39554" txt_i="28580" txt_f="28581">P</offsets></italic><offsets xml_i="39563" xml_f="39730" txt_i="28581" txt_f="28748"> = 0.029), indicative of an effect that cannot be attributed to the physical exercise program. No significant differences could be detected for the fold change of CCR5</offsets><sup><offsets xml_i="39735" xml_f="39736" txt_i="28748" txt_f="28749">+</offsets></sup><offsets xml_i="39742" xml_f="39751" txt_i="28749" txt_f="28758"> and CD86</offsets><sup><offsets xml_i="39756" xml_f="39757" txt_i="28758" txt_f="28759">+</offsets></sup><offsets xml_i="39763" xml_f="39819" txt_i="28759" txt_f="28815"> pDC nor for the secreted amount of IL-6, IL-12p70, TNF-</offsets><italic><offsets xml_i="39827" xml_f="39828" txt_i="28815" txt_f="28816">α</offsets></italic><offsets xml_i="39837" xml_f="39843" txt_i="28816" txt_f="28822">, IFN-</offsets><italic><offsets xml_i="39851" xml_f="39852" txt_i="28822" txt_f="28823">α</offsets></italic><offsets xml_i="39861" xml_f="39969" txt_i="28823" txt_f="28931">, caspase-1, and MMP-9 upon IQ stimulation between trained and sedentary MS patients after 12 weeks (Tables </offsets><xref ref-type="table" rid="tab3"><offsets xml_i="40003" xml_f="40004" txt_i="28931" txt_f="28932">3</offsets></xref><offsets xml_i="40011" xml_f="40016" txt_i="28932" txt_f="28937"> and </offsets><xref ref-type="table" rid="tab4"><offsets xml_i="40050" xml_f="40051" txt_i="28937" txt_f="28938">4</offsets></xref><offsets xml_i="40058" xml_f="40060" txt_i="28938" txt_f="28940">).</offsets></p></sec><sec id="sec3.6"><title><offsets xml_i="40094" xml_f="40177" txt_i="28942" txt_f="29025">3.6. Circulating Treg Subsets Are Not Affected by Long-Term Physical Exercise in MS</offsets></title><p><offsets xml_i="40188" xml_f="40294" txt_i="29026" txt_f="29132">Using flow cytometry, we next characterized the effect of physical exercise on Treg subsets, that is, CD25</offsets><sup><offsets xml_i="40299" xml_f="40301" txt_i="29132" txt_f="29134">hi</offsets></sup><offsets xml_i="40307" xml_f="40312" txt_i="29134" txt_f="29139">FoxP3</offsets><sup><offsets xml_i="40317" xml_f="40318" txt_i="29139" txt_f="29140">+</offsets></sup><offsets xml_i="40324" xml_f="40340" txt_i="29140" txt_f="29156">, Tr1, and Th3 (</offsets><xref ref-type="table" rid="tab5"><offsets xml_i="40374" xml_f="40381" txt_i="29156" txt_f="29163">Table 5</offsets></xref><offsets xml_i="40388" xml_f="40390" txt_i="29163" txt_f="29165">).</offsets></p><p><offsets xml_i="40397" xml_f="40724" txt_i="29166" txt_f="29493">In our hands, no effect of the 12-week combined exercise program on the proportion of Treg populations could be detected. Similarly, no effect was observed in the sedentary control group. Interestingly, a positive correlation was found at log-log scale between the proportion of IL-10-producing Tr1 cells and the number of CD80</offsets><sup><offsets xml_i="40729" xml_f="40730" txt_i="29493" txt_f="29494">+</offsets></sup><offsets xml_i="40736" xml_f="40742" txt_i="29494" txt_f="29500"> pDC (</offsets><italic><offsets xml_i="40750" xml_f="40751" txt_i="29500" txt_f="29501">P</offsets></italic><offsets xml_i="40760" xml_f="40770" txt_i="29501" txt_f="29511"> = 0.001, </offsets><italic><offsets xml_i="40778" xml_f="40779" txt_i="29511" txt_f="29512">ρ</offsets></italic><offsets xml_i="40788" xml_f="40798" txt_i="29512" txt_f="29522"> = 0.383; </offsets><xref ref-type="fig" rid="fig3"><offsets xml_i="40830" xml_f="40838" txt_i="29522" txt_f="29530">Figure 3</offsets></xref><offsets xml_i="40845" xml_f="40847" txt_i="29530" txt_f="29532">).</offsets></p></sec></sec><sec id="sec4"><title><offsets xml_i="40885" xml_f="40898" txt_i="29535" txt_f="29548">4. Discussion</offsets></title><p><offsets xml_i="40909" xml_f="41471" txt_i="29549" txt_f="30111">Based on previously demonstrated improvements in muscle strength, cardiovascular health, mental functioning, and quality of life in MS patients participating in an exercise program, we examined the modulation of immune variables that are known to impact disease activity in MS, namely, cellular and molecular mediators of innate immunity, following a 12-week combined exercise program in this study. This hypothesis is supported by studies investigating the effect of physical exercise in the experimental autoimmune encephalomyelitis (EAE) animal model for MS [</offsets><xref rid="B8" ref-type="bibr"><offsets xml_i="41502" xml_f="41503" txt_i="30111" txt_f="30112">8</offsets></xref><offsets xml_i="41510" xml_f="41512" txt_i="30112" txt_f="30114">].</offsets></p><p><offsets xml_i="41519" xml_f="41672" txt_i="30115" txt_f="30268">We were not able to detect differences following 12 weeks of exercise for the IL-6 and IL-12p70 serum concentration, similar to findings made by others [</offsets><xref rid="B34" ref-type="bibr"><offsets xml_i="41704" xml_f="41706" txt_i="30268" txt_f="30270">34</offsets></xref><offsets xml_i="41713" xml_f="41714" txt_i="30270" txt_f="30271">–</offsets><xref rid="B36" ref-type="bibr"><offsets xml_i="41746" xml_f="41748" txt_i="30271" txt_f="30273">36</offsets></xref><offsets xml_i="41755" xml_f="41824" txt_i="30273" txt_f="30342">]. Likewise, no differences in the serum concentration of IL-10, TNF-</offsets><italic><offsets xml_i="41832" xml_f="41833" txt_i="30342" txt_f="30343">α</offsets></italic><offsets xml_i="41842" xml_f="41999" txt_i="30343" txt_f="30500">, caspase-1, and MMP-9 were found following the exercise program. After an exercise program in MS patients, White et al. found decreased IL-10 serum levels [</offsets><xref rid="B35" ref-type="bibr"><offsets xml_i="42031" xml_f="42033" txt_i="30500" txt_f="30502">35</offsets></xref><offsets xml_i="42040" xml_f="42053" txt_i="30502" txt_f="30515">], while TNF-</offsets><italic><offsets xml_i="42061" xml_f="42062" txt_i="30515" txt_f="30516">α</offsets></italic><offsets xml_i="42071" xml_f="42096" txt_i="30516" txt_f="30541"> serum levels increased [</offsets><xref rid="B36" ref-type="bibr"><offsets xml_i="42128" xml_f="42130" txt_i="30541" txt_f="30543">36</offsets></xref><offsets xml_i="42137" xml_f="42151" txt_i="30543" txt_f="30557">], decreased [</offsets><xref rid="B35" ref-type="bibr"><offsets xml_i="42183" xml_f="42185" txt_i="30557" txt_f="30559">35</offsets></xref><offsets xml_i="42192" xml_f="42218" txt_i="30559" txt_f="30585">], or remained unchanged [</offsets><xref rid="B34" ref-type="bibr"><offsets xml_i="42250" xml_f="42252" txt_i="30585" txt_f="30587">34</offsets></xref><offsets xml_i="42259" xml_f="42292" txt_i="30587" txt_f="30620">]. MMP-9 serum levels increased [</offsets><xref rid="B37" ref-type="bibr"><offsets xml_i="42324" xml_f="42326" txt_i="30620" txt_f="30622">37</offsets></xref><offsets xml_i="42333" xml_f="42349" txt_i="30622" txt_f="30638">] or decreased [</offsets><xref rid="B38" ref-type="bibr"><offsets xml_i="42381" xml_f="42383" txt_i="30638" txt_f="30640">38</offsets></xref><offsets xml_i="42390" xml_f="42707" txt_i="30640" txt_f="30957">] following an exercise program in healthy men and men with metabolic syndrome, respectively. The different outcomes of the various studies could be attributed to the variability in training protocols and study populations or to the different techniques used to quantify the secreted levels of inflammatory mediators.</offsets></p><p><offsets xml_i="42714" xml_f="42759" txt_i="30958" txt_f="31003">Interestingly, we demonstrated decreased TNF-</offsets><italic><offsets xml_i="42767" xml_f="42768" txt_i="31003" txt_f="31004">α</offsets></italic><offsets xml_i="42777" xml_f="42849" txt_i="31004" txt_f="31076"> and MMP-9 secretion following whole blood stimulation with LPS and IFN-</offsets><italic><offsets xml_i="42857" xml_f="42858" txt_i="31076" txt_f="31077">γ</offsets></italic><offsets xml_i="42867" xml_f="43015" txt_i="31077" txt_f="31225"> in trained MS patients, which may be of potential interest in disease-mediated pathways. We hypothesize that the observed reduced secretion of TNF-</offsets><italic><offsets xml_i="43023" xml_f="43024" txt_i="31225" txt_f="31226">α</offsets></italic><offsets xml_i="43033" xml_f="43236" txt_i="31226" txt_f="31429"> might contribute to a diminished stimulation of myelin-specific Th1 and Th17 effector cells, ultimately resulting in attenuated disease activity. In support of this, reduced frequencies of LPS- and IFN-</offsets><italic><offsets xml_i="43244" xml_f="43245" txt_i="31429" txt_f="31430">γ</offsets></italic><offsets xml_i="43254" xml_f="43368" txt_i="31430" txt_f="31544">-stimulated cytokine-producing monocytes and cDC were found in elite swimmers after long-term intensive training [</offsets><xref rid="B39" ref-type="bibr"><offsets xml_i="43400" xml_f="43402" txt_i="31544" txt_f="31546">39</offsets></xref><offsets xml_i="43409" xml_f="43555" txt_i="31546" txt_f="31692">]. Furthermore, reduced LPS-induced cytokine production by monocyte-derived DC resulted in diminished stimulation of Th1 and Th17 effector cells [</offsets><xref rid="B40" ref-type="bibr"><offsets xml_i="43587" xml_f="43589" txt_i="31692" txt_f="31694">40</offsets></xref><offsets xml_i="43596" xml_f="43887" txt_i="31694" txt_f="31985">]. In addition, the observed reduced secretion of MMP-9 might positively affect blood-brain barrier integrity. Indeed, the primary role of MMP-9 is degradation of the extracellular matrix, for example, during blood-brain barrier transmigration of leukocytes to the CNS, which is seen in MS [</offsets><xref rid="B41" ref-type="bibr"><offsets xml_i="43919" xml_f="43921" txt_i="31985" txt_f="31987">41</offsets></xref><offsets xml_i="43928" xml_f="43996" txt_i="31987" txt_f="32055">]. Together with the significantly more pronounced reduction in CCR5</offsets><sup><offsets xml_i="44001" xml_f="44002" txt_i="32055" txt_f="32056">+</offsets></sup><offsets xml_i="44008" xml_f="44030" txt_i="32056" txt_f="32078"> cDC upon LPS and IFN-</offsets><italic><offsets xml_i="44038" xml_f="44039" txt_i="32078" txt_f="32079">γ</offsets></italic><offsets xml_i="44048" xml_f="44327" txt_i="32079" txt_f="32358"> stimulation observed in MS patients who participated in the exercise program, this may suggest that exercise affects the migratory potential of cDC, although functional studies are needed to confirm this. In contrast to our findings, a reduction in LPS-induced secretion of IL-1</offsets><italic><offsets xml_i="44335" xml_f="44336" txt_i="32358" txt_f="32359">β</offsets></italic><offsets xml_i="44345" xml_f="44421" txt_i="32359" txt_f="32435">, IL-6, and IL-12 was observed after long-term physical exercise by others [</offsets><xref rid="B39" ref-type="bibr"><offsets xml_i="44453" xml_f="44455" txt_i="32435" txt_f="32437">39</offsets></xref><offsets xml_i="44462" xml_f="44887" txt_i="32437" txt_f="32862">]. Nevertheless, further experiments are mandatory to identify the responsible cell types secreting the inflammatory mediators as well as to determine whether long-term exercise affects the surface expression of TLR resulting in the observed reduced secretion of inflammatory mediators. Indeed, whereas higher expression levels of TLR2 and TLR4 were found on mononuclear cells in MS patients as compared to healthy controls [</offsets><xref rid="B42" ref-type="bibr"><offsets xml_i="44919" xml_f="44921" txt_i="32862" txt_f="32864">42</offsets></xref><offsets xml_i="44928" xml_f="45059" txt_i="32864" txt_f="32995">], a reduction in the expression levels of TLR could potentially mediate the favourable effect of physical exercise in MS patients.</offsets></p><p><offsets xml_i="45066" xml_f="45353" txt_i="32996" txt_f="33283">No effect of exercise on the absolute number of cDC could be detected, as indicated by an increase in cDC numbers after the 12-week time period in both study groups. It has been demonstrated that changes in frequency of circulating myeloid cells correlate with certain chronic diseases [</offsets><xref rid="B43" ref-type="bibr"><offsets xml_i="45385" xml_f="45387" txt_i="33283" txt_f="33285">43</offsets></xref><offsets xml_i="45394" xml_f="45504" txt_i="33285" txt_f="33395">]. Previously, we showed decreased numbers of circulating pDC in MS patients as compared to healthy controls [</offsets><xref rid="B22" ref-type="bibr"><offsets xml_i="45536" xml_f="45538" txt_i="33395" txt_f="33397">22</offsets></xref><offsets xml_i="45545" xml_f="45630" txt_i="33397" txt_f="33482">]. Interestingly, in this study, increased cell counts of pDC, more specifically CD80</offsets><sup><offsets xml_i="45635" xml_f="45636" txt_i="33482" txt_f="33483">+</offsets></sup><offsets xml_i="45642" xml_f="45656" txt_i="33483" txt_f="33497"> pDC and CD62L</offsets><sup><offsets xml_i="45661" xml_f="45662" txt_i="33497" txt_f="33498">+</offsets></sup><offsets xml_i="45668" xml_f="46014" txt_i="33498" txt_f="33844"> pDC, were found after 12 weeks of exercise, indicative of an activated phenotype. However, others have reported conflicting results. Indeed, Chiang et al. found that healthy practitioners of Tai-Chi Chuan, an aerobic exercise of moderate intensity, showed increased numbers of circulating cDC, but not pDC, as compared to sedentary individuals [</offsets><xref rid="B26" ref-type="bibr"><offsets xml_i="46046" xml_f="46048" txt_i="33844" txt_f="33846">26</offsets></xref><offsets xml_i="46055" xml_f="46213" txt_i="33846" txt_f="34004">]. Also in obese individuals an increased proportion of cDC, but a decreased proportion of pDC, was observed after 10 weeks of intensified exercise training [</offsets><xref rid="B27" ref-type="bibr"><offsets xml_i="46245" xml_f="46247" txt_i="34004" txt_f="34006">27</offsets></xref><offsets xml_i="46254" xml_f="46420" txt_i="34006" txt_f="34172">]. Noteworthy, in the same study no differences regarding cDC and pDC numbers were observed in lean individuals. However, a sedentary control group was not included [</offsets><xref rid="B27" ref-type="bibr"><offsets xml_i="46452" xml_f="46454" txt_i="34172" txt_f="34174">27</offsets></xref><offsets xml_i="46461" xml_f="46572" txt_i="34174" txt_f="34285">]. Others recently demonstrated that natalizumab treatment of MS also increases the number of circulating pDC [</offsets><xref rid="B44" ref-type="bibr"><offsets xml_i="46604" xml_f="46606" txt_i="34285" txt_f="34287">44</offsets></xref><offsets xml_i="46613" xml_f="46810" txt_i="34287" txt_f="34484">]. However, in our hands no effect of natalizumab treatment on the reported findings could be observed (data not shown). Furthermore, we observed a significant increase in the fold change of HLA-DR</offsets><sup><offsets xml_i="46815" xml_f="46816" txt_i="34484" txt_f="34485">+</offsets></sup><offsets xml_i="46822" xml_f="47053" txt_i="34485" txt_f="34716"> pDC upon IQ stimulation after completion of the exercise program. This may suggest an increase in the number of pDC contributing to antigen presentation upon TLR stimulation in MS patients who participated in the exercise program.</offsets></p><p><offsets xml_i="47060" xml_f="47263" txt_i="34717" txt_f="34920">Based on our observations demonstrating increased numbers of activated pDC following the 12-week combined exercise program as well as on the role of activated pDC in inducing IL-10-producing Treg (Tr1) [</offsets><xref rid="B21" ref-type="bibr"><offsets xml_i="47295" xml_f="47297" txt_i="34920" txt_f="34922">21</offsets></xref><offsets xml_i="47304" xml_f="47665" txt_i="34922" txt_f="35283">], we hypothesized increased numbers of Tr1 in MS patients who completed the exercise program. Whereas in our hands no effect of long-term physical exercise on the proportion of Treg populations could be observed, others previously reported that individuals who participated in a long-term physical exercise program show higher proportions of circulating Treg [</offsets><xref rid="B45" ref-type="bibr"><offsets xml_i="47697" xml_f="47699" txt_i="35283" txt_f="35285">45</offsets></xref><offsets xml_i="47706" xml_f="47824" txt_i="35285" txt_f="35403">]. Importantly, we demonstrate a positive correlation between the proportion of Tr1 and the number of circulating CD80</offsets><sup><offsets xml_i="47829" xml_f="47830" txt_i="35403" txt_f="35404">+</offsets></sup><offsets xml_i="47836" xml_f="48221" txt_i="35404" txt_f="35789"> pDC, underscoring the hypothesis that increasing numbers of activated pDC may drive the induction of Treg following long-term physical exercise in MS. However, the role of pDC in immunity and tolerance appears complex and activated pDC also participate in innate immunity with a specialized production of type I IFN. In doing so, pDC can stimulate the proliferation of naive T cells [</offsets><xref rid="B46" ref-type="bibr"><offsets xml_i="48253" xml_f="48255" txt_i="35789" txt_f="35791">46</offsets></xref><offsets xml_i="48262" xml_f="48344" txt_i="35791" txt_f="35873">], albeit poorly relative to cDC. Nevertheless, no effect on the secretion of IFN-</offsets><italic><offsets xml_i="48352" xml_f="48353" txt_i="35873" txt_f="35874">α</offsets></italic><offsets xml_i="48362" xml_f="49173" txt_i="35874" txt_f="36685"> by pDC upon TLR7 stimulation was observed following physical exercise in this study. Hence, it is less likely that increased activated pDC numbers induce effector T cell stimulation following long-term physical exercise, further supporting promotion of the immunoregulatory function of pDC. Future experiments are needed to understand the role of pDC in managing both innate and adaptive immune responses, for example, expression of inducible tolerogenic enzyme indoleamine 2,3-dioxygenase (IDO), inducible costimulator ligand (ICOS-L), and/or programmed death 1 ligand (PD-L1), which mediate Treg development, and how this is affected by long-term exercise. Additional prognostic studies addressing associations between immunologic effects of long-term exercise and clinical changes in MS patients are needed.</offsets></p><p><offsets xml_i="49180" xml_f="49373" txt_i="36686" txt_f="36879">In this respect, it has been proposed that exercise stress influences the immune system via the activation of the HPA axis and the sympathetic nervous system, two main neuroendocrine pathways [</offsets><xref rid="B47" ref-type="bibr"><offsets xml_i="49405" xml_f="49407" txt_i="36879" txt_f="36881">47</offsets></xref><offsets xml_i="49414" xml_f="49887" txt_i="36881" txt_f="37354">]. It is known that their respective signaling molecules, cortisol, DHEA, and catecholamines modulate the number, functioning, trafficking, and activity of immune cells. Hence, evaluating the hormonal release could offer insight into the mechanisms that underlie exercise-mediated immune modulation. Unfortunately, in our hands, no physiologically relevant changes in serum cortisol and DHEA levels after the exercise program could be observed, in line with other studies [</offsets><xref rid="B48" ref-type="bibr"><offsets xml_i="49919" xml_f="49921" txt_i="37354" txt_f="37356">48</offsets></xref><offsets xml_i="49928" xml_f="50098" txt_i="37356" txt_f="37526">]. However, it is possible that a change in serum cortisol and DHEA levels is only elicited by a more intensive training program, as demonstrated by others for cortisol [</offsets><xref rid="B39" ref-type="bibr"><offsets xml_i="50130" xml_f="50132" txt_i="37526" txt_f="37528">39</offsets></xref><offsets xml_i="50139" xml_f="50372" txt_i="37528" txt_f="37761">]. Finally, future studies should test different exercise intensities, to define a minimal exercise intensity where effects on the immune and/or neuroendocrine system, for example, cortisol, DHEA, and catecholamines, can be detected.</offsets></p><p><offsets xml_i="50379" xml_f="50464" txt_i="37762" txt_f="37847">In conclusion, we confirmed that long-term physical exercise is safe in MS patients [</offsets><xref rid="B49" ref-type="bibr"><offsets xml_i="50496" xml_f="50498" txt_i="37847" txt_f="37849">49</offsets></xref><offsets xml_i="50505" xml_f="51575" txt_i="37849" txt_f="38919">], as evidenced by no changes observed in the serum levels of proinflammatory mediators following the exercise program. In addition, the annualized relapse rate was not significantly different between the exercise (0.45 per year) and the sedentary group (0.35 per year). However, long-term follow-up of patients participating in physical exercise programs remains necessary. Based on our observations, we conclude a shift towards a tolerogenic profile after physical exercise, suggesting a favourable immunologic effect in MS. Indeed, we demonstrated increased numbers of activated pDC, associated with Tr1 development, and decreased secretion of TLR-induced inflammatory mediators in MS patients following the 12-week combined endurance and resistance exercise program. Noteworthy, whether these immune-modulatory effects occur in every subject undergoing a training program or are specific for MS patients needs to be addressed in future studies. Overall, our results suggest that long-term physical exercise favourably impacts the underlying immunopathogenesis of MS.</offsets></p></sec><sec sec-type="supplementary-material" id="supplementary-material-sec"><title><offsets xml_i="51663" xml_f="51685" txt_i="38921" txt_f="38943">Supplementary Material</offsets></title><supplementary-material content-type="local-data" id="f1"><caption><p><offsets xml_i="51763" xml_f="52017" txt_i="38944" txt_f="39198">Supplementary Appendix: Description of the statistical approach of 12 weeks of combined endurance and resistance training reduces innate markers of inflammation in a randomized controlled clinical trial in patients with multiple sclerosis by Deckx et al.</offsets></p><p><offsets xml_i="52024" xml_f="52099" txt_i="39199" txt_f="39274">Supplementary Table 1: Detailed patient characteristics and medication use.</offsets></p></caption><media xlink:href="6789276.f1.doc" mimetype="application" mime-subtype="msword" orientation="portrait" id="d35e1065" position="anchor"></media></supplementary-material></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to thank all MS patients for participating in this study. This work was supported by Grant no. G.0168.09 of the Fund for Scientific Research-Flanders, Belgium (FWO-Vlaanderen). Further support was provided through the Special Research Fund (BOF), a BOF-GOA grant (ID PS 28313), Medical Legacy Fund (UZA), the Methusalem Funding Program, the Belgian Hercules Foundation, the Belgian Charcot Foundation, and the “Belgische Stichting Roeping.” Amber H. Nuyts held a Ph.D. fellowship from the Flemish Institute for Science and Technology (IWT). Nathalie Cools held a postdoctoral fellowship of the Fund for Scientific Research-Flanders (FWO-Vlaanderen).</p></ack><sec sec-type="conflict"><title>Conflict of Interests</title><p>The authors declare that there is no conflict of interests regarding the publication of this paper.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Compston</surname><given-names>A.</given-names></name><name><surname>Coles</surname><given-names>A.</given-names></name></person-group><article-title>Multiple sclerosis</article-title><source><italic>The Lancet</italic></source><year>2002</year><volume>359</volume><issue>9313</issue><fpage>1221</fpage><lpage>1231</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(02)08220-x</pub-id><pub-id pub-id-type="other">2-s2.0-0037029424</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalgas</surname><given-names>U.</given-names></name><name><surname>Stenager</surname><given-names>E.</given-names></name><name><surname>Ingemann-Hansen</surname><given-names>T.</given-names></name></person-group><article-title>Multiple sclerosis and physical exercise: recommendations for the application of resistance-, endurance- and combined training</article-title><source><italic>Multiple Sclerosis</italic></source><year>2008</year><volume>14</volume><issue>1</issue><fpage>35</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1177/1352458507079445</pub-id><pub-id pub-id-type="other">2-s2.0-42149176067</pub-id><pub-id pub-id-type="pmid">17881393</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broekmans</surname><given-names>T.</given-names></name><name><surname>Roelants</surname><given-names>M.</given-names></name><name><surname>Feys</surname><given-names>P.</given-names></name><etal></etal></person-group><article-title>Effects of long-term resistance training and simultaneous electro-stimulation on muscle strength and functional mobility in multiple sclerosis</article-title><source><italic>Multiple Sclerosis</italic></source><year>2011</year><volume>17</volume><issue>4</issue><fpage>468</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1177/1352458510391339</pub-id><pub-id pub-id-type="other">2-s2.0-79954585472</pub-id><pub-id pub-id-type="pmid">21148266</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Çakt</surname><given-names>B. D.</given-names></name><name><surname>Nacir</surname><given-names>B.</given-names></name><name><surname>Genç</surname><given-names>H.</given-names></name><etal></etal></person-group><article-title>Cycling progressive resistance training for people with multiple sclerosis: a randomized controlled study</article-title><source><italic>American Journal of Physical Medicine and Rehabilitation</italic></source><year>2010</year><volume>89</volume><issue>6</issue><fpage>446</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1097/phm.0b013e3181d3e71f</pub-id><pub-id pub-id-type="other">2-s2.0-77952952864</pub-id><pub-id pub-id-type="pmid">20216060</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stroud</surname><given-names>N. M.</given-names></name><name><surname>Minahan</surname><given-names>C. L.</given-names></name></person-group><article-title>The impact of regular physical activity on fatigue, depression and quality of life in persons with multiple sclerosis</article-title><source><italic>Health and Quality of Life Outcomes</italic></source><year>2009</year><volume>7, article 68</volume><pub-id pub-id-type="doi">10.1186/1477-7525-7-68</pub-id><pub-id pub-id-type="other">2-s2.0-68449088776</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wens</surname><given-names>I.</given-names></name><name><surname>Hansen</surname><given-names>D.</given-names></name><name><surname>Verboven</surname><given-names>K.</given-names></name><etal></etal></person-group><article-title>Impact of 24 weeks of resistance and endurance exercise on glucose tolerance in persons with multiple sclerosis</article-title><source><italic>American Journal of Physical Medicine &amp; Rehabilitation</italic></source><year>2015</year><volume>94</volume><issue>10, supplement 1</issue><fpage>838</fpage><lpage>847</lpage><pub-id pub-id-type="pmid">25768064</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garner</surname><given-names>D. J. P.</given-names></name><name><surname>Widrick</surname><given-names>J. J.</given-names></name></person-group><article-title>Cross-bridge mechanisms of muscle weakness in multiple sclerosis</article-title><source><italic>Muscle and Nerve</italic></source><year>2003</year><volume>27</volume><issue>4</issue><fpage>456</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1002/mus.10346</pub-id><pub-id pub-id-type="other">2-s2.0-0037380349</pub-id><pub-id pub-id-type="pmid">12661047</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pryor</surname><given-names>W. M.</given-names></name><name><surname>Freeman</surname><given-names>K. G.</given-names></name><name><surname>Larson</surname><given-names>R. D.</given-names></name><name><surname>Edwards</surname><given-names>G. L.</given-names></name><name><surname>White</surname><given-names>L. J.</given-names></name></person-group><article-title>Chronic exercise confers neuroprotection in experimental autoimmune encephalomyelitis</article-title><source><italic>Journal of Neuroscience Research</italic></source><year>2015</year><volume>93</volume><issue>5</issue><fpage>697</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1002/jnr.23528</pub-id><pub-id pub-id-type="pmid">25510644</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giovannoni</surname><given-names>G.</given-names></name><name><surname>Ebers</surname><given-names>G.</given-names></name></person-group><article-title>Multiple sclerosis: the environment and causation</article-title><source><italic>Current Opinion in Neurology</italic></source><year>2007</year><volume>20</volume><issue>3</issue><fpage>261</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1097/wco.0b013e32815610c2</pub-id><pub-id pub-id-type="other">2-s2.0-34248364052</pub-id><pub-id pub-id-type="pmid">17495618</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giunti</surname><given-names>D.</given-names></name><name><surname>Borsellino</surname><given-names>G.</given-names></name><name><surname>Benelli</surname><given-names>R.</given-names></name><etal></etal></person-group><article-title>Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS</article-title><source><italic>Journal of Leukocyte Biology</italic></source><year>2003</year><volume>73</volume><issue>5</issue><fpage>584</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1189/jlb.1202598</pub-id><pub-id pub-id-type="other">2-s2.0-0037824666</pub-id><pub-id pub-id-type="pmid">12714572</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gandhi</surname><given-names>R.</given-names></name><name><surname>Laroni</surname><given-names>A.</given-names></name><name><surname>Weiner</surname><given-names>H. L.</given-names></name></person-group><article-title>Role of the innate immune system in the pathogenesis of multiple sclerosis</article-title><source><italic>Journal of Neuroimmunology</italic></source><year>2010</year><volume>221</volume><issue>1-2</issue><fpage>7</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2009.10.015</pub-id><pub-id pub-id-type="other">2-s2.0-77951214891</pub-id><pub-id pub-id-type="pmid">19931190</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cools</surname><given-names>N.</given-names></name><name><surname>Petrizzo</surname><given-names>A.</given-names></name><name><surname>Smits</surname><given-names>E.</given-names></name><etal></etal></person-group><article-title>Dendritic cells in the pathogenesis and treatment of human diseases: a Janus Bifrons?</article-title><source><italic>Immunotherapy</italic></source><year>2011</year><volume>3</volume><issue>10</issue><fpage>1203</fpage><lpage>1222</lpage><pub-id pub-id-type="doi">10.2217/imt.11.110</pub-id><pub-id pub-id-type="other">2-s2.0-80054118073</pub-id><pub-id pub-id-type="pmid">21995572</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacDonald</surname><given-names>K. P. A.</given-names></name><name><surname>Munster</surname><given-names>D. J.</given-names></name><name><surname>Clark</surname><given-names>G. J.</given-names></name><name><surname>Dzionek</surname><given-names>A.</given-names></name><name><surname>Schmitz</surname><given-names>J.</given-names></name><name><surname>Hart</surname><given-names>D. N. J.</given-names></name></person-group><article-title>Characterization of human blood dendritic cell subsets</article-title><source><italic>Blood</italic></source><year>2002</year><volume>100</volume><issue>13</issue><fpage>4512</fpage><lpage>4520</lpage><pub-id pub-id-type="doi">10.1182/blood-2001-11-0097</pub-id><pub-id pub-id-type="other">2-s2.0-0037114743</pub-id><pub-id pub-id-type="pmid">12393628</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollender</surname><given-names>P.</given-names></name><name><surname>Ittelet</surname><given-names>D.</given-names></name><name><surname>Villard</surname><given-names>F.</given-names></name><name><surname>Eymard</surname><given-names>J.-C.</given-names></name><name><surname>Jeannesson</surname><given-names>P.</given-names></name><name><surname>Bernard</surname><given-names>J.</given-names></name></person-group><article-title>Active matrix metalloprotease-9 in and migration pattern of dendritic cells matured in clinical grade culture conditions</article-title><source><italic>Immunobiology</italic></source><year>2002</year><volume>206</volume><issue>4</issue><fpage>441</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1078/0171-2985-00193</pub-id><pub-id pub-id-type="other">2-s2.0-0036774410</pub-id><pub-id pub-id-type="pmid">12437074</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cella</surname><given-names>M.</given-names></name><name><surname>Jarrossay</surname><given-names>D.</given-names></name><name><surname>Faccheth</surname><given-names>F.</given-names></name><etal></etal></person-group><article-title>Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon</article-title><source><italic>Nature Medicine</italic></source><year>1999</year><volume>5</volume><issue>8</issue><fpage>919</fpage><lpage>923</lpage><pub-id pub-id-type="doi">10.1038/11360</pub-id><pub-id pub-id-type="other">2-s2.0-0032773794</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elkon</surname><given-names>K. B.</given-names></name><name><surname>Wiedeman</surname><given-names>A.</given-names></name></person-group><article-title>Type I IFN system in the development and manifestations of SLE</article-title><source><italic>Current Opinion in Rheumatology</italic></source><year>2012</year><volume>24</volume><issue>5</issue><fpage>499</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1097/bor.0b013e3283562c3e</pub-id><pub-id pub-id-type="other">2-s2.0-84864874057</pub-id><pub-id pub-id-type="pmid">22832823</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>N. M.</given-names></name><name><surname>Isenberg</surname><given-names>J. S.</given-names></name><name><surname>Thomson</surname><given-names>A. W.</given-names></name></person-group><article-title>Plasmacytoid dendritic cells: no longer an enigma and now key to transplant tolerance?</article-title><source><italic>American Journal of Transplantation</italic></source><year>2013</year><volume>13</volume><issue>5</issue><fpage>1125</fpage><lpage>1133</lpage><pub-id pub-id-type="doi">10.1111/ajt.12229</pub-id><pub-id pub-id-type="other">2-s2.0-84876934665</pub-id><pub-id pub-id-type="pmid">23617754</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karrich</surname><given-names>J. J.</given-names></name><name><surname>Jachimowski</surname><given-names>L. C. M.</given-names></name><name><surname>Uittenbogaart</surname><given-names>C. H.</given-names></name><name><surname>Blom</surname><given-names>B.</given-names></name></person-group><article-title>The plasmacytoid dendritic cell as the swiss army knife of the immune system: molecular regulation of its multifaceted functions</article-title><source><italic>Journal of Immunology</italic></source><year>2014</year><volume>193</volume><issue>12</issue><fpage>5772</fpage><lpage>5778</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1401541</pub-id><pub-id pub-id-type="other">2-s2.0-84916912403</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goubier</surname><given-names>A.</given-names></name><name><surname>Dubois</surname><given-names>B.</given-names></name><name><surname>Gheit</surname><given-names>H.</given-names></name><etal></etal></person-group><article-title>Plasmacytoid dendritic cells mediate oral tolerance</article-title><source><italic>Immunity</italic></source><year>2008</year><volume>29</volume><issue>3</issue><fpage>464</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2008.06.017</pub-id><pub-id pub-id-type="other">2-s2.0-51349158548</pub-id><pub-id pub-id-type="pmid">18789731</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matta</surname><given-names>B. M.</given-names></name><name><surname>Castellaneta</surname><given-names>A.</given-names></name><name><surname>Thomson</surname><given-names>A. W.</given-names></name></person-group><article-title>Tolerogenic plasmacytoid DC</article-title><source><italic>European Journal of Immunology</italic></source><year>2010</year><volume>40</volume><issue>10</issue><fpage>2667</fpage><lpage>2676</lpage><pub-id pub-id-type="doi">10.1002/eji.201040839</pub-id><pub-id pub-id-type="other">2-s2.0-77957108257</pub-id><pub-id pub-id-type="pmid">20821731</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>T.</given-names></name><name><surname>Yang</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>Y.-H.</given-names></name><etal></etal></person-group><article-title>Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand</article-title><source><italic>Journal of Experimental Medicine</italic></source><year>2007</year><volume>204</volume><issue>1</issue><fpage>105</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1084/jem.20061660</pub-id><pub-id pub-id-type="other">2-s2.0-33846438598</pub-id><pub-id pub-id-type="pmid">17200410</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thewissen</surname><given-names>K.</given-names></name><name><surname>Nuyts</surname><given-names>A. H.</given-names></name><name><surname>Deckx</surname><given-names>N.</given-names></name><etal></etal></person-group><article-title>Circulating dendritic cells of multiple sclerosis patients are proinflammatory and their frequency is correlated with MS-associated genetic risk factors</article-title><source><italic>Multiple Sclerosis</italic></source><year>2014</year><volume>20</volume><issue>5</issue><fpage>548</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1177/1352458513505352</pub-id><pub-id pub-id-type="other">2-s2.0-84899094125</pub-id><pub-id pub-id-type="pmid">24057429</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stasiolek</surname><given-names>M.</given-names></name><name><surname>Bayas</surname><given-names>A.</given-names></name><name><surname>Kruse</surname><given-names>N.</given-names></name><etal></etal></person-group><article-title>Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis</article-title><source><italic>Brain</italic></source><year>2006</year><volume>129</volume><issue>5</issue><fpage>1293</fpage><lpage>1305</lpage><pub-id pub-id-type="doi">10.1093/brain/awl043</pub-id><pub-id pub-id-type="other">2-s2.0-33646233989</pub-id><pub-id pub-id-type="pmid">16513684</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>N. P.</given-names></name><name><surname>Gleeson</surname><given-names>M.</given-names></name><name><surname>Shephard</surname><given-names>R. J.</given-names></name><etal></etal></person-group><article-title>Position statement. Part one. Immune function and exercise</article-title><source><italic>Exercise Immunology Review</italic></source><year>2011</year><volume>17</volume><fpage>6</fpage><lpage>63</lpage><pub-id pub-id-type="other">2-s2.0-79953775784</pub-id><pub-id pub-id-type="pmid">21446352</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>L.-M.</given-names></name><name><surname>Chen</surname><given-names>Y.-J.</given-names></name><name><surname>Chiang</surname><given-names>J.</given-names></name><name><surname>Lai</surname><given-names>L.-Y.</given-names></name><name><surname>Chen</surname><given-names>Y.-Y.</given-names></name><name><surname>Liao</surname><given-names>H.-F.</given-names></name></person-group><article-title>Modulation of dendritic cells by endurance training</article-title><source><italic>International Journal of Sports Medicine</italic></source><year>2007</year><volume>28</volume><issue>9</issue><fpage>798</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.1055/s-2007-964914</pub-id><pub-id pub-id-type="other">2-s2.0-34548661284</pub-id><pub-id pub-id-type="pmid">17436203</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>Y.-Y.</given-names></name><name><surname>Akiko</surname><given-names>T.</given-names></name><etal></etal></person-group><article-title>Tai Chi Chuan increases circulating myeloid dendritic cells</article-title><source><italic>Immunological Investigations</italic></source><year>2010</year><volume>39</volume><issue>8</issue><fpage>863</fpage><lpage>873</lpage><pub-id pub-id-type="doi">10.3109/08820139.2010.503766</pub-id><pub-id pub-id-type="other">2-s2.0-77958173295</pub-id><pub-id pub-id-type="pmid">20718659</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nickel</surname><given-names>T.</given-names></name><name><surname>Hanssen</surname><given-names>H.</given-names></name><name><surname>Emslander</surname><given-names>I.</given-names></name><etal></etal></person-group><article-title>Immunomodulatory effects of aerobic training in obesity</article-title><source><italic>Mediators of Inflammation</italic></source><year>2011</year><volume>2011</volume><fpage>10</fpage><pub-id pub-id-type="publisher-id">308965</pub-id><pub-id pub-id-type="doi">10.1155/2011/308965</pub-id><pub-id pub-id-type="other">2-s2.0-79955025117</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polman</surname><given-names>C. H.</given-names></name><name><surname>Reingold</surname><given-names>S. C.</given-names></name><name><surname>Banwell</surname><given-names>B.</given-names></name><etal></etal></person-group><article-title>Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria</article-title><source><italic>Annals of Neurology</italic></source><year>2011</year><volume>69</volume><issue>2</issue><fpage>292</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1002/ana.22366</pub-id><pub-id pub-id-type="other">2-s2.0-79952501096</pub-id><pub-id pub-id-type="pmid">21387374</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>M. E.</given-names></name></person-group><article-title>Chronic stress and immunosenescence: a review</article-title><source><italic>Neuroimmunomodulation</italic></source><year>2008</year><volume>15</volume><issue>4–6</issue><fpage>241</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1159/000156467</pub-id><pub-id pub-id-type="other">2-s2.0-57149100571</pub-id><pub-id pub-id-type="pmid">19047801</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moriguchi Jeckel</surname><given-names>C. M.</given-names></name><name><surname>Lopes</surname><given-names>R. P.</given-names></name><name><surname>Berleze</surname><given-names>M. C.</given-names></name><etal></etal></person-group><article-title>Neuroendocrine and immunological correlates of chronic stress in ‘strictly healthy’ populations</article-title><source><italic>NeuroImmunoModulation</italic></source><year>2010</year><volume>17</volume><issue>1</issue><fpage>9</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1159/000243080</pub-id><pub-id pub-id-type="other">2-s2.0-70349820985</pub-id><pub-id pub-id-type="pmid">19816052</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Verbeke</surname><given-names>G.</given-names></name><name><surname>Molenberghs</surname><given-names>G.</given-names></name></person-group><source><italic>Linear Mixed Models for Longitudinal Data</italic></source><year>2000</year><publisher-loc>New York, NY, USA</publisher-loc><publisher-name>Springer</publisher-name><pub-id pub-id-type="doi">10.1007/978-1-4419-0300-6</pub-id><pub-id pub-id-type="other">MR1880596</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banchereau</surname><given-names>J.</given-names></name><name><surname>Briere</surname><given-names>F.</given-names></name><name><surname>Caux</surname><given-names>C.</given-names></name><etal></etal></person-group><article-title>Immunobiology of dendritic cells</article-title><source><italic>Annual Review of Immunology</italic></source><year>2000</year><volume>18</volume><fpage>767</fpage><lpage>811</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.18.1.767</pub-id><pub-id pub-id-type="other">2-s2.0-0034041033</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tough</surname><given-names>D. F.</given-names></name></person-group><article-title>Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation</article-title><source><italic>Leukemia and Lymphoma</italic></source><year>2004</year><volume>45</volume><issue>2</issue><fpage>257</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1080/1042819031000149368</pub-id><pub-id pub-id-type="other">2-s2.0-0842301509</pub-id><pub-id pub-id-type="pmid">15101709</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bansi</surname><given-names>J.</given-names></name><name><surname>Bloch</surname><given-names>W.</given-names></name><name><surname>Gamper</surname><given-names>U.</given-names></name><name><surname>Kesselring</surname><given-names>J.</given-names></name></person-group><article-title>Training in MS: influence of two different endurance training protocols (aquatic versus overland) on cytokine and neurotrophin concentrations during three week randomized controlled trial</article-title><source><italic>Multiple Sclerosis</italic></source><year>2013</year><volume>19</volume><issue>5</issue><fpage>613</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.1177/1352458512458605</pub-id><pub-id pub-id-type="other">2-s2.0-84876546570</pub-id><pub-id pub-id-type="pmid">22936334</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>L. J.</given-names></name><name><surname>Castellano</surname><given-names>V.</given-names></name><name><surname>McCoy</surname><given-names>S. C.</given-names></name></person-group><article-title>Cytokine responses to resistance training in people with multiple sclerosis</article-title><source><italic>Journal of Sports Sciences</italic></source><year>2006</year><volume>24</volume><issue>8</issue><fpage>911</fpage><lpage>914</lpage><pub-id pub-id-type="doi">10.1080/02640410500357036</pub-id><pub-id pub-id-type="other">2-s2.0-33745917423</pub-id><pub-id pub-id-type="pmid">16815786</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castellano</surname><given-names>V.</given-names></name><name><surname>Patel</surname><given-names>D. I.</given-names></name><name><surname>White</surname><given-names>L. J.</given-names></name></person-group><article-title>Cytokine responses to acute and chronic exercise in multiple sclerosis</article-title><source><italic>Journal of Applied Physiology</italic></source><year>2008</year><volume>104</volume><issue>6</issue><fpage>1697</fpage><lpage>1702</lpage><pub-id pub-id-type="doi">10.1152/japplphysiol.00954.2007</pub-id><pub-id pub-id-type="other">2-s2.0-49649124892</pub-id><pub-id pub-id-type="pmid">18388249</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urso</surname><given-names>M. L.</given-names></name><name><surname>Pierce</surname><given-names>J. R.</given-names></name><name><surname>Alemany</surname><given-names>J. A.</given-names></name><name><surname>Harman</surname><given-names>E. A.</given-names></name><name><surname>Nindl</surname><given-names>B. C.</given-names></name></person-group><article-title>Effects of exercise training on the matrix metalloprotease response to acute exercise</article-title><source><italic>European Journal of Applied Physiology</italic></source><year>2009</year><volume>106</volume><issue>5</issue><fpage>655</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1007/s00421-009-1063-0</pub-id><pub-id pub-id-type="other">2-s2.0-67650312617</pub-id><pub-id pub-id-type="pmid">19404671</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>C. K.</given-names></name><name><surname>Won</surname><given-names>D.</given-names></name><name><surname>Pruthi</surname><given-names>S.</given-names></name><etal></etal></person-group><article-title>Effect of a short-term diet and exercise intervention on oxidative stress, inflammation, MMP-9, and monocyte chemotactic activity in men with metabolic syndrome factors</article-title><source><italic>Journal of Applied Physiology</italic></source><year>2006</year><volume>100</volume><issue>5</issue><fpage>1657</fpage><lpage>1665</lpage><pub-id pub-id-type="doi">10.1152/japplphysiol.01292.2005</pub-id><pub-id pub-id-type="other">2-s2.0-33646429745</pub-id><pub-id pub-id-type="pmid">16357066</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgado</surname><given-names>J. M.</given-names></name><name><surname>Rama</surname><given-names>L.</given-names></name><name><surname>Silva</surname><given-names>I.</given-names></name><etal></etal></person-group><article-title>Cytokine production by monocytes, neutrophils, and dendritic cells is hampered by long-term intensive training in elite swimmers</article-title><source><italic>European Journal of Applied Physiology</italic></source><year>2012</year><volume>112</volume><issue>2</issue><fpage>471</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1007/s00421-011-1966-4</pub-id><pub-id pub-id-type="other">2-s2.0-84856543585</pub-id><pub-id pub-id-type="pmid">21584686</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Draper</surname><given-names>E.</given-names></name><name><surname>DeCourcey</surname><given-names>J.</given-names></name><name><surname>Higgins</surname><given-names>S. C.</given-names></name><etal></etal></person-group><article-title>Conjugated linoleic acid suppresses dendritic cell activation and subsequent Th17 responses</article-title><source><italic>Journal of Nutritional Biochemistry</italic></source><year>2014</year><volume>25</volume><issue>7</issue><fpage>741</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1016/j.jnutbio.2014.03.004</pub-id><pub-id pub-id-type="other">2-s2.0-84901856464</pub-id><pub-id pub-id-type="pmid">24794016</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yen</surname><given-names>J.-H.</given-names></name><name><surname>Khayrullina</surname><given-names>T.</given-names></name><name><surname>Ganea</surname><given-names>D.</given-names></name></person-group><article-title>PGE2-induced metalloproteinase-9 is essential for dendritic cell migration</article-title><source><italic>Blood</italic></source><year>2008</year><volume>111</volume><issue>1</issue><fpage>260</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1182/blood-2007-05-090613</pub-id><pub-id pub-id-type="other">2-s2.0-38049156464</pub-id><pub-id pub-id-type="pmid">17925490</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasheminia</surname><given-names>S. J.</given-names></name><name><surname>Zarkesh-Esfahani</surname><given-names>S. H.</given-names></name><name><surname>Tolouei</surname><given-names>S.</given-names></name><name><surname>Shaygannejad</surname><given-names>V.</given-names></name><name><surname>Shirzad</surname><given-names>H.</given-names></name><name><surname>Hashemzadeh</surname><given-names>C. M.</given-names></name></person-group><article-title>Toll like receptor 2 and 4 expression in peripheral blood mononuclear cells of multiple sclerosis patients</article-title><source><italic>Iranian Journal of Immunology</italic></source><year>2014</year><volume>11</volume><fpage>74</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">24975964</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verschoor</surname><given-names>C. P.</given-names></name><name><surname>Johnstone</surname><given-names>J.</given-names></name><name><surname>Millar</surname><given-names>J.</given-names></name><etal></etal></person-group><article-title>Alterations to the frequency and function of peripheral blood monocytes and associations with chronic disease in the advanced-age, frail elderly</article-title><source><italic>PLoS ONE</italic></source><year>2014</year><volume>9</volume><issue>8</issue><pub-id pub-id-type="publisher-id">e104522</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0104522</pub-id><pub-id pub-id-type="other">2-s2.0-84905649973</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kivisäkk</surname><given-names>P.</given-names></name><name><surname>Francois</surname><given-names>K.</given-names></name><name><surname>Mbianda</surname><given-names>J.</given-names></name><name><surname>Gandhi</surname><given-names>R.</given-names></name><name><surname>Weiner</surname><given-names>H. L.</given-names></name><name><surname>Khoury</surname><given-names>S. J.</given-names></name></person-group><article-title>Effect of natalizumab treatment on circulating plasmacytoid dendritic cells: a cross-sectional observational study in patients with multiple sclerosis</article-title><source><italic>PLoS ONE</italic></source><year>2014</year><volume>9</volume><issue>7</issue><pub-id pub-id-type="publisher-id">e103716</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0103716</pub-id><pub-id pub-id-type="other">2-s2.0-84904981406</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>S.-H.</given-names></name><name><surname>Chuang</surname><given-names>H.</given-names></name><name><surname>Lin</surname><given-names>L.-W.</given-names></name><name><surname>Hsiao</surname><given-names>C.-Y.</given-names></name><name><surname>Wang</surname><given-names>P.-W.</given-names></name><name><surname>Yang</surname><given-names>K. D.</given-names></name></person-group><article-title>Tai chi chuan exercise decreases A1C levels along with increase of regulatory T-cells and decrease of cytotoxic T-cell population in type 2 diabetic patients</article-title><source><italic>Diabetes Care</italic></source><year>2007</year><volume>30</volume><issue>3</issue><fpage>716</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.2337/dc06-1507</pub-id><pub-id pub-id-type="other">2-s2.0-33847619372</pub-id><pub-id pub-id-type="pmid">17327347</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villadangos</surname><given-names>J. A.</given-names></name><name><surname>Young</surname><given-names>L.</given-names></name></person-group><article-title>Antigen-presentation properties of plasmacytoid dendritic cells</article-title><source><italic>Immunity</italic></source><year>2008</year><volume>29</volume><issue>3</issue><fpage>352</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2008.09.002</pub-id><pub-id pub-id-type="other">2-s2.0-51349099789</pub-id><pub-id pub-id-type="pmid">18799143</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deckx</surname><given-names>N.</given-names></name><name><surname>Lee</surname><given-names>W.-P.</given-names></name><name><surname>Berneman</surname><given-names>Z. N.</given-names></name><name><surname>Cools</surname><given-names>N.</given-names></name></person-group><article-title>Neuroendocrine immunoregulation in multiple sclerosis</article-title><source><italic>Clinical and Developmental Immunology</italic></source><year>2013</year><volume>2013</volume><fpage>23</fpage><pub-id pub-id-type="publisher-id">705232</pub-id><pub-id pub-id-type="doi">10.1155/2013/705232</pub-id><pub-id pub-id-type="other">2-s2.0-84893713796</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heaney</surname><given-names>J. L. J.</given-names></name><name><surname>Carroll</surname><given-names>D.</given-names></name><name><surname>Phillips</surname><given-names>A. C.</given-names></name></person-group><article-title>DHEA, DHEA-S and cortisol responses to acute exercise in older adults in relation to exercise training status and sex</article-title><source><italic>Age</italic></source><year>2013</year><volume>35</volume><issue>2</issue><fpage>395</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1007/s11357-011-9345-y</pub-id><pub-id pub-id-type="other">2-s2.0-84880551735</pub-id><pub-id pub-id-type="pmid">22105939</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pilutti</surname><given-names>L. A.</given-names></name><name><surname>Platta</surname><given-names>M. E.</given-names></name><name><surname>Motl</surname><given-names>R. W.</given-names></name><name><surname>Latimer-Cheung</surname><given-names>A. E.</given-names></name></person-group><article-title>The safety of exercise training in multiple sclerosis: a systematic review</article-title><source><italic>Journal of the Neurological Sciences</italic></source><year>2014</year><volume>343</volume><issue>1-2</issue><fpage>3</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2014.05.016</pub-id><pub-id pub-id-type="other">2-s2.0-84904247905</pub-id><pub-id pub-id-type="pmid">24880538</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Flow diagram of patient enrolment.</p></caption><graphic xlink:href="MI2016-6789276.001"></graphic></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Increased numbers of activated pDC are found following a 12-week combined exercise program in MS. Enumeration of the absolute number of circulating pDC (a) and cDC (b) was determined by means of a double platform method using an automatic cell counter and flow cytometry before start of the study (open bars) and after 12 weeks (filled bars). The activation state (c, d) and the migratory profile (e, f) of DC were assessed by enumerating pDC and cDC expressing CD80, CD86, CD62L, CCR5, and CCR7. Results are shown as mean absolute number ± SEM. <sup><italic>∗</italic></sup>
<italic>P</italic> &lt; 0.05. cDC, conventional dendritic cells; pDC, plasmacytoid dendritic cells; EX, exercise group; SED, sedentary control group; SEM, standard error of the mean.</p></caption><graphic xlink:href="MI2016-6789276.002"></graphic></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Positive correlation at log-log scale between the proportion of Tr1 and the number of CD80<sup>+</sup> pDC. A positive correlation at log-log scale was found between the proportion of Tr1 cells and the number of CD80<sup>+</sup> pDC (<italic>P</italic> = 0.001; <italic>ρ</italic> = 0.383). Both variables were log-transformed to obtain a normal distribution. pDC, plasmacytoid dendritic cells; Tr1, type 1 regulatory T cell; log, logarithmic transformation; <italic>ρ</italic>, Pearson's correlation coefficient.</p></caption><graphic xlink:href="MI2016-6789276.003"></graphic></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Clinical details of the study population.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"> </th><th align="center" rowspan="1" colspan="1">EX</th><th align="center" rowspan="1" colspan="1">SED</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic> values</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Gender (M/F)</td><td align="center" rowspan="1" colspan="1">13/16</td><td align="center" rowspan="1" colspan="1">6/10</td><td align="center" rowspan="1" colspan="1">0.634</td></tr><tr><td align="left" rowspan="1" colspan="1">Age ± SEM</td><td align="center" rowspan="1" colspan="1">47 ± 2</td><td align="center" rowspan="1" colspan="1">50 ± 3</td><td align="center" rowspan="1" colspan="1">0.516</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI ± SEM</td><td align="center" rowspan="1" colspan="1">24 ± 1</td><td align="center" rowspan="1" colspan="1">24 ± 1</td><td align="center" rowspan="1" colspan="1">0.821</td></tr><tr><td align="left" rowspan="1" colspan="1">EDSS ± SEM</td><td align="center" rowspan="1" colspan="1">3 ± 0.2</td><td align="center" rowspan="1" colspan="1">3 ± 0.4</td><td align="center" rowspan="1" colspan="1">0.155</td></tr><tr><td align="left" rowspan="1" colspan="1">Type MS (CP/RR)</td><td align="center" rowspan="1" colspan="1">10/19</td><td align="center" rowspan="1" colspan="1">5/11</td><td align="center" rowspan="1" colspan="1">0.826</td></tr><tr><td align="left" rowspan="1" colspan="1">Medication (untreated/1st-line treatment/2nd-line treatment)</td><td align="center" rowspan="1" colspan="1">4/16/9</td><td align="center" rowspan="1" colspan="1">2/8/6</td><td align="center" rowspan="1" colspan="1">0.908</td></tr></tbody></table><table-wrap-foot><fn><p>Results are shown as mean ± SEM. Patients were defined as untreated when a wash-out period of at least 3 months was respected before recruitment in the study. 1st-line treatment: IFN-<italic>β</italic> (Avonex, Betaferon, and Rebif) and glatiramer acetate (Copaxone); 2nd-line treatment: alemtuzumab (Campath), natalizumab (Tysabri), and fingolimod (Gilenya).</p></fn><fn><p>EX, exercise group; SED, sedentary control group; M, male; F, female; BMI, body mass index; EDSS, expanded disability status scale; MS, multiple sclerosis; CP, chronically progressive MS; RR, relapsing-remitting MS; SEM, standard error of the mean.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Serum signaling molecule concentrations are not altered following long-term physical exercise in MS.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Molecule</th><th align="center" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">Time</th><th align="center" rowspan="1" colspan="1">Mean concentration (pg/mL) ± SEM</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic> values</th></tr></thead><tbody><tr><td align="left" rowspan="4" colspan="1">IL-6</td><td align="center" rowspan="2" colspan="1">EX</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">0.60 ± 0.09</td><td align="center" rowspan="2" colspan="1">0.434</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">0.54 ± 0.09</td></tr><tr><td align="center" rowspan="2" colspan="1">SED</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">0.45 ± 0.09</td><td align="center" rowspan="2" colspan="1">0.341</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">0.54 ± 0.09</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr></hr>
</td></tr><tr><td align="left" rowspan="4" colspan="1">IL-10</td><td align="center" rowspan="2" colspan="1">EX</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">0.48 ± 0.09</td><td align="center" rowspan="2" colspan="1">0.731</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">0.50 ± 0.09</td></tr><tr><td align="center" rowspan="2" colspan="1">SED</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">0.60 ± 0.19</td><td align="center" rowspan="2" colspan="1">0.097</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">0.31 ± 0.04</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr></hr>
</td></tr><tr><td align="left" rowspan="4" colspan="1">IL-12p70</td><td align="center" rowspan="2" colspan="1">EX</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">0.09 ± 0.01</td><td align="center" rowspan="2" colspan="1">0.312</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">0.12 ± 0.02</td></tr><tr><td align="center" rowspan="2" colspan="1">SED</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">0.13 ± 0.03</td><td align="center" rowspan="2" colspan="1">1.000</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">0.13 ± 0.02</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr></hr>
</td></tr><tr><td align="left" rowspan="4" colspan="1">TNF-<italic>α</italic>
</td><td align="center" rowspan="2" colspan="1">EX</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">1.07 ± 0.11</td><td align="center" rowspan="2" colspan="1">1.000</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">1.05 ± 0.10</td></tr><tr><td align="center" rowspan="2" colspan="1">SED</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">1.37 ± 0.18</td><td align="center" rowspan="2" colspan="1">0.665</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">1.23 ± 0.16</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr></hr>
</td></tr><tr><td align="left" rowspan="4" colspan="1">Caspase-1</td><td align="center" rowspan="2" colspan="1">EX</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">100.48 ± 9.78</td><td align="center" rowspan="2" colspan="1">0.217</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">112.97 ± 9.81</td></tr><tr><td align="center" rowspan="2" colspan="1">SED</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">121.61 ± 25.43</td><td align="center" rowspan="2" colspan="1">1.000</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">100.00 ± 14.64</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr></hr>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Molecule</td><td align="center" rowspan="1" colspan="1">Group</td><td align="center" rowspan="1" colspan="1">Time</td><td align="center" rowspan="1" colspan="1">Mean concentration (ng/mL) ± SEM</td><td align="center" rowspan="1" colspan="1">
<italic>P</italic> values</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr></hr>
</td></tr><tr><td align="left" rowspan="4" colspan="1">MMP-9</td><td align="center" rowspan="2" colspan="1">EX</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">192.35 ± 23.43</td><td align="center" rowspan="2" colspan="1">1.000</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">174.40 ± 17.84</td></tr><tr><td align="center" rowspan="2" colspan="1">SED</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">208.36 ± 25.59</td><td align="center" rowspan="2" colspan="1">0.368</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">176.32 ± 20.86</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr></hr>
</td></tr><tr><td align="left" rowspan="4" colspan="1">DHEA</td><td align="center" rowspan="2" colspan="1">EX</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">16.11 ± 1.65</td><td align="center" rowspan="2" colspan="1">0.300</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">17.06 ± 1.98</td></tr><tr><td align="center" rowspan="2" colspan="1">SED</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">16.08 ± 2.17</td><td align="center" rowspan="2" colspan="1">1.000</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">16.18 ± 1.90</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr></hr>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Molecule</td><td align="center" rowspan="1" colspan="1">Group</td><td align="center" rowspan="1" colspan="1">Time</td><td align="center" rowspan="1" colspan="1">Mean concentration (<italic>µ</italic>g/dL) ± SEM</td><td align="center" rowspan="1" colspan="1">
<italic>P</italic> values</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr></hr>
</td></tr><tr><td align="left" rowspan="4" colspan="1">Cortisol</td><td align="center" rowspan="2" colspan="1">EX</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">22.17 ± 1.73</td><td align="center" rowspan="2" colspan="1">
<bold>0.047</bold>
</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">23.73 ± 1.74</td></tr><tr><td align="center" rowspan="2" colspan="1">SED</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">20.07 ± 1.00</td><td align="center" rowspan="2" colspan="1">0.110</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">21.49 ± 0.78</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr></hr>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Molecule</td><td align="center" rowspan="1" colspan="1">Group</td><td align="center" rowspan="1" colspan="1">Time</td><td align="center" rowspan="1" colspan="1">Mean molar ratio ± SEM</td><td align="center" rowspan="1" colspan="1">
<italic>P</italic> values</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr></hr>
</td></tr><tr><td align="left" rowspan="4" colspan="1">Cortisol/DHEA </td><td align="center" rowspan="2" colspan="1">EX</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">13.78 ± 1.41</td><td align="center" rowspan="2" colspan="1">0.716</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">14.50 ± 1.57</td></tr><tr><td align="center" rowspan="2" colspan="1">SED</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">12.18 ± 1.44</td><td align="center" rowspan="2" colspan="1">0.234</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">12.80 ± 1.34</td></tr></tbody></table><table-wrap-foot><fn><p>The serum concentration of signaling molecules was measured with ELISA, and the molar ratio of cortisol to DHEA was calculated. Results are shown as mean concentration or molar ratio ± SEM.</p></fn><fn><p>IL, interleukin; TNF, tumour necrosis factor; MMP, matrix metalloproteinase; DHEA, dehydroepiandrosterone; EX, exercise group; SED, sedentary control group; PRE, baseline measurement; POST, measurement after 12 weeks; SEM, standard error of the mean.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>A 12-week exercise program induces a decreased fold change of CCR5<sup>+</sup> cDC upon LPS and IFN-<italic>γ</italic> stimulation and an increased fold change of HLA-DR<sup>+</sup> pDC upon IQ stimulation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Marker</th><th align="center" rowspan="2" colspan="1">Group</th><th align="center" rowspan="2" colspan="1">Time</th><th align="center" colspan="2" rowspan="1">cDC</th><th align="center" colspan="2" rowspan="1">pDC</th></tr><tr><th align="center" rowspan="1" colspan="1">Mean fold change ± SEM</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic> values</th><th align="center" rowspan="1" colspan="1">Mean fold change ± SEM</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic> values</th></tr></thead><tbody><tr><td align="left" rowspan="4" colspan="1">CCR5</td><td align="center" rowspan="2" colspan="1">EX</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">0.59 ± 0.06</td><td align="center" rowspan="2" colspan="1">
<bold>0.002</bold>
</td><td align="center" rowspan="1" colspan="1">1.45 ± 0.28</td><td align="center" rowspan="2" colspan="1">1.000</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">0.38 ± 0.06</td><td align="center" rowspan="1" colspan="1">1.98 ± 0.61</td></tr><tr><td align="center" rowspan="2" colspan="1">SED</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">0.51 ± 0.06</td><td align="center" rowspan="2" colspan="1">1.000</td><td align="center" rowspan="1" colspan="1">1.67 ± 0.37</td><td align="center" rowspan="2" colspan="1">0.184</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">0.56 ± 0.09</td><td align="center" rowspan="1" colspan="1">2.08 ± 0.98</td></tr><tr><td align="center" colspan="7" rowspan="1">
<hr></hr>
</td></tr><tr><td align="left" rowspan="4" colspan="1">CD86</td><td align="center" rowspan="2" colspan="1">EX</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">2.68 ± 0.45</td><td align="center" rowspan="2" colspan="1">0.100</td><td align="center" rowspan="1" colspan="1">12.34 ± 2.55</td><td align="center" rowspan="2" colspan="1">0.383</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">2.12 ± 0.23</td><td align="center" rowspan="1" colspan="1">9.14 ± 2.11</td></tr><tr><td align="center" rowspan="2" colspan="1">SED</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">2.44 ± 0.48</td><td align="center" rowspan="2" colspan="1">1.000</td><td align="center" rowspan="1" colspan="1">5.70 ± 1.56</td><td align="center" rowspan="2" colspan="1">0.767</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">2.84 ± 0.69</td><td align="center" rowspan="1" colspan="1">5.95 ± 2.73</td></tr><tr><td align="center" colspan="7" rowspan="1">
<hr></hr>
</td></tr><tr><td align="left" rowspan="4" colspan="1">HLA-DR</td><td align="center" rowspan="2" colspan="1">EX</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">1.01 ± 0.01</td><td align="center" rowspan="2" colspan="1">0.189</td><td align="center" rowspan="1" colspan="1">0.90 ± 0.03</td><td align="center" rowspan="2" colspan="1">
<bold>0.008</bold>
</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">1.01 ± 0.01</td><td align="center" rowspan="1" colspan="1">0.97 ± 0.02</td></tr><tr><td align="center" rowspan="2" colspan="1">SED</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">1.06 ± 0.06</td><td align="center" rowspan="2" colspan="1">0.439</td><td align="center" rowspan="1" colspan="1">0.92 ± 0.06</td><td align="center" rowspan="2" colspan="1">0.609</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">1.06 ± 0.03</td><td align="center" rowspan="1" colspan="1">0.82 ± 0.08</td></tr></tbody></table><table-wrap-foot><fn><p>Blood samples were stimulated overnight with LPS in combination with IFN-<italic>γ</italic>, or IQ. The percentage of CCR5, CD86, and HLA-DR positive cDC and pDC after TLR stimulation was measured using flow cytometry. Mean fold changes are calculated as the ratio of the proportion of CCR5, CD86, and HLA-DR positive cDC and pDC in the stimulated condition to the nonstimulated condition. Results are shown as mean fold change ± SEM.</p></fn><fn><p>cDC, conventional dendritic cells; pDC, plasmacytoid dendritic cells; LPS, lipopolysaccharide; IQ, imiquimod; EX, exercise group; SED, sedentary group; PRE, baseline measurement; POST, measurement after 12 weeks; SEM, standard error of the mean.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Exercise results in decreased secretion of the inflammatory mediators, TNF-<italic>α</italic> and MMP-9, upon LPS and IFN-<italic>γ</italic> stimulation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Inflammatory mediator</th><th align="center" rowspan="2" colspan="1">Group</th><th align="center" rowspan="2" colspan="1">Time</th><th align="center" colspan="2" rowspan="1">LPS + IFN-<italic>γ</italic>
</th><th align="center" colspan="2" rowspan="1">IQ</th></tr><tr><th align="center" rowspan="1" colspan="1">Mean fold change ± SEM</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic> values</th><th align="center" rowspan="1" colspan="1">Mean fold change ± SEM</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic> values</th></tr></thead><tbody><tr><td align="left" rowspan="4" colspan="1">IL-1<italic>β</italic>
</td><td align="center" rowspan="2" colspan="1">EX</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">89.3 ± 11.5</td><td align="center" rowspan="2" colspan="1">0.461</td><td align="center" rowspan="1" colspan="1">2.2 ± 0.2</td><td align="center" rowspan="2" colspan="1">0.790</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">77.1 ± 11.5</td><td align="center" rowspan="1" colspan="1">2.0 ± 0.2</td></tr><tr><td align="center" rowspan="2" colspan="1">SED</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">94.1 ± 19.5</td><td align="center" rowspan="2" colspan="1">0.258</td><td align="center" rowspan="1" colspan="1">2.7 ± 0.6</td><td align="center" rowspan="2" colspan="1">
<bold>0.029</bold>
</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">72.0 ± 16.9</td><td align="center" rowspan="1" colspan="1">1.8 ± 0.4</td></tr><tr><td align="center" colspan="7" rowspan="1">
<hr></hr>
</td></tr><tr><td align="left" rowspan="4" colspan="1">IL-6</td><td align="center" rowspan="2" colspan="1">EX</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">111.0 ± 7.7</td><td align="center" rowspan="2" colspan="1">1.000</td><td align="center" rowspan="1" colspan="1">15.7 ± 2.1</td><td align="center" rowspan="2" colspan="1">1.000</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">110.8 ± 6.5</td><td align="center" rowspan="1" colspan="1">15.9 ± 2.5</td></tr><tr><td align="center" rowspan="2" colspan="1">SED</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">103.5 ± 12.8</td><td align="center" rowspan="2" colspan="1">0.782</td><td align="center" rowspan="1" colspan="1">16.8 ± 3.1</td><td align="center" rowspan="2" colspan="1">1.000</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">109.7 ± 11.0</td><td align="center" rowspan="1" colspan="1">14.5 ± 3.4</td></tr><tr><td align="center" colspan="7" rowspan="1">
<hr></hr>
</td></tr><tr><td align="left" rowspan="4" colspan="1">IL-12p70</td><td align="center" rowspan="2" colspan="1">EX</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">26.0 ± 7.6</td><td align="center" rowspan="2" colspan="1">0.313</td><td align="center" rowspan="1" colspan="1">1.2 ± 0.1</td><td align="center" rowspan="2" colspan="1">1.000</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">15.2 ± 4.1</td><td align="center" rowspan="1" colspan="1">1.2 ± 0.2</td></tr><tr><td align="center" rowspan="2" colspan="1">SED</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">18.1 ± 6.4</td><td align="center" rowspan="2" colspan="1">1.000</td><td align="center" rowspan="1" colspan="1">1.6 ± 0.4</td><td align="center" rowspan="2" colspan="1">0.410</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">19.5 ± 6.8</td><td align="center" rowspan="1" colspan="1">2.2 ± 0.6</td></tr><tr><td align="center" colspan="7" rowspan="1">
<hr></hr>
</td></tr><tr><td align="left" rowspan="4" colspan="1">TNF-<italic>α</italic>
</td><td align="center" rowspan="2" colspan="1">EX</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">55.1 ± 5.7</td><td align="center" rowspan="2" colspan="1">
<bold>0.028</bold>
</td><td align="center" rowspan="1" colspan="1">1.6 ± 0.1</td><td align="center" rowspan="2" colspan="1">0.926</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">39.2 ± 4.4</td><td align="center" rowspan="1" colspan="1">1.5 ± 0.1</td></tr><tr><td align="center" rowspan="2" colspan="1">SED</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">43.9 ± 8.0</td><td align="center" rowspan="2" colspan="1">1.000</td><td align="center" rowspan="1" colspan="1">1.6 ± 0.2</td><td align="center" rowspan="2" colspan="1">0.168</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">46.5 ± 9.3</td><td align="center" rowspan="1" colspan="1">1.3 ± 0.2</td></tr><tr><td align="center" colspan="7" rowspan="1">
<hr></hr>
</td></tr><tr><td align="left" rowspan="4" colspan="1">IFN-<italic>α</italic>
</td><td align="center" rowspan="2" colspan="1">EX</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">2.1 ± 0.6</td><td align="center" rowspan="2" colspan="1">1.000</td><td align="center" rowspan="1" colspan="1">7.4 ± 1.2</td><td align="center" rowspan="2" colspan="1">1.000</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">2.7 ± 0.9</td><td align="center" rowspan="1" colspan="1">8.0 ± 1.6</td></tr><tr><td align="center" rowspan="1" colspan="1">SED</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">1.9 ± 0.8</td><td align="center" rowspan="2" colspan="1">1.000</td><td align="center" rowspan="1" colspan="1">6.7 ± 1.8</td><td align="center" rowspan="2" colspan="1">0.231</td></tr><tr><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">1.7 ± 0.6</td><td align="center" rowspan="1" colspan="1">4.4 ± 1.0</td></tr><tr><td align="center" colspan="7" rowspan="1">
<hr></hr>
</td></tr><tr><td align="left" rowspan="4" colspan="1">Caspase-1</td><td align="center" rowspan="2" colspan="1">EX</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">8.8 ± 0.7</td><td align="center" rowspan="2" colspan="1">0.604</td><td align="center" rowspan="1" colspan="1">4.8 ± 0.7</td><td align="center" rowspan="2" colspan="1">0.260</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">8.0 ± 0.7</td><td align="center" rowspan="1" colspan="1">3.6 ± 0.4</td></tr><tr><td align="center" rowspan="2" colspan="1">SED</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">8.1 ± 1.0</td><td align="center" rowspan="2" colspan="1">1.000</td><td align="center" rowspan="1" colspan="1">3.6 ± 0.6</td><td align="center" rowspan="2" colspan="1">1.000</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">6.8 ± 0.8</td><td align="center" rowspan="1" colspan="1">3.8 ± 0.9</td></tr><tr><td align="center" colspan="7" rowspan="1">
<hr></hr>
</td></tr><tr><td align="left" rowspan="4" colspan="1">MMP-9</td><td align="center" rowspan="2" colspan="1">EX</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">7.9 ± 0.8</td><td align="center" rowspan="2" colspan="1">
<bold>0.040</bold>
</td><td align="center" rowspan="1" colspan="1">2.2 ± 0.2</td><td align="center" rowspan="2" colspan="1">1.000</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">6.2 ± 0.5</td><td align="center" rowspan="1" colspan="1">2.1 ± 0.1</td></tr><tr><td align="center" rowspan="2" colspan="1">SED</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">6.5 ± 1.0</td><td align="center" rowspan="2" colspan="1">0.233</td><td align="center" rowspan="1" colspan="1">2.0 ± 0.2</td><td align="center" rowspan="2" colspan="1">1.000</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">6.4 ± 0.6</td><td align="center" rowspan="1" colspan="1">2.0 ± 0.3</td></tr></tbody></table><table-wrap-foot><fn><p>Blood samples were stimulated overnight with LPS in combination with IFN-<italic>γ</italic>, or IQ. Secretion of inflammatory mediators was quantified using ELISA. Mean fold changes are calculated as the ratio of the secreted concentration in the stimulated condition to the nonstimulated condition. Results are shown as mean fold change ± SEM.</p></fn><fn><p>LPS, lipopolysaccharide; IQ, imiquimod; IL, interleukin; TNF, tumor necrosis factor; IFN, interferon; MMP, matrix metalloproteinase; EX, exercise group; SED, sedentary control group; PRE, baseline measurement; POST, measurement after 12 weeks; SEM, standard error of the mean. </p></fn></table-wrap-foot></table-wrap><table-wrap id="tab5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Circulating Treg subsets are not affected by long-term physical exercise in MS.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Treg subset</th><th align="center" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">Time</th><th align="center" rowspan="1" colspan="1">Mean % Treg in CD4<sup>+</sup> T cell population ± SEM</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic> values</th></tr></thead><tbody><tr><td align="left" rowspan="4" colspan="1">CD25<sup>hi</sup>FoxP3<sup>+</sup>
</td><td align="center" rowspan="2" colspan="1">EX</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">0.62 ± 0.11</td><td align="center" rowspan="2" colspan="1">0.083</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">1.12 ± 0.41</td></tr><tr><td align="center" rowspan="2" colspan="1">SED</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">1.00 ± 0.30</td><td align="center" rowspan="2" colspan="1">0.782</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">1.69 ± 0.85</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr></hr>
</td></tr><tr><td align="left" rowspan="4" colspan="1">IL-10<sup>+</sup> (Tr1)</td><td align="center" rowspan="2" colspan="1">EX</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">0.22 ± 0.05</td><td align="center" rowspan="2" colspan="1">1.000</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">0.20 ± 0.02</td></tr><tr><td align="center" rowspan="2" colspan="1">SED</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">0.33 ± 0.09</td><td align="center" rowspan="2" colspan="1">0.796</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">0.50 ± 0.26</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr></hr>
</td></tr><tr><td align="left" rowspan="4" colspan="1">TGF-<italic>β</italic>
<sup>+</sup> (Th3)</td><td align="center" rowspan="2" colspan="1">EX</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">0.15 ± 0.02</td><td align="center" rowspan="2" colspan="1">1.000</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">0.19 ± 0.09</td></tr><tr><td align="center" rowspan="2" colspan="1">SED</td><td align="center" rowspan="1" colspan="1">PRE</td><td align="center" rowspan="1" colspan="1">0.17 ± 0.04</td><td align="center" rowspan="2" colspan="1">0.056</td></tr><tr><td align="center" rowspan="1" colspan="1">POST</td><td align="center" rowspan="1" colspan="1">0.12 ± 0.08</td></tr></tbody></table><table-wrap-foot><fn><p>The percentage of circulating Treg subsets was determined using flow cytometry. Results are shown as mean percentage ± SEM.</p></fn><fn><p>Treg, regulatory T cell; FoxP3, forkhead box P3; IL, interleukin; Tr1, type 1 regulatory T cell; TGF, transforming growth factor; Th3, T helper 3 cell; EX, exercise group; SED, sedentary control group; PRE, baseline measurement; POST, measurement after 12 weeks; SEM, standard error of the mean.</p></fn></table-wrap-foot></table-wrap></floats-group></article>